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Abstract
Malaria is the parasitic disease that affects the most humans, with
Plasmodium falciparum malaria being responsible for the majority of
severe malaria and malaria related deaths. The asexual form of the para-
site causes the signs and symptoms associated with malaria infection. The
sexual form of the parasite, also known as a gametocyte, is the stage re-
sponsible for infectivity of the human host (patient) to the mosquito vector
and thus ongoing transmission of malaria and the spread of antimalarial
drug resistance. Historically malaria therapeutic efficacy studies have fo-
cused mainly on the clearance of asexual parasites. However, malaria in a
community can only be truly combated if a treatment program is imple-
mented that is able to clear both asexual and sexual parasites effectively.
In this thesis focus will be on the modeling of the key features of ga-
metocytemia (the presence of gametocytes in a host’s system). Particular
emphasis will be on the modeling of the time to gametocyte emergence,
the density of gametocytes and the duration of gametocytemia. It is also
of interest to investigate the impact of the administered treatment on the
aforementioned features.
Gametocyte data has several interesting features. Firstly, the distri-
bution of gametocyte data is zero-inflated with a long-tail to the right.
The observed longitudinal gametocyte profile also has a nonlinear rela-
tionship with time. In addition, since most malaria intervention studies
are not designed to optimally measure the evolution of the longitudinal
gametocyte profile, there are very few observation points in the time pe-
riod where the gametocyte profile is expected to peak. Gametocyte data
collected from malaria intervention studies are also affected by informative
censoring, which leads to incomplete gametocyte profiles. An example of
informative censoring is when a patient who experiences treatment failure
is “rescued” and withdrawn, from the study in order to receive alternative
treatment. This patient can be considered to be in worse health as com-
pared to the patients who remain in this study. There are also competing
risks of exit from the study, as a patient can either experience treatment
failure or be lost-to-follow-up.
The aforementioned features of gametocyte data make it statistically
appealing to analyze. In literature there are several modeling techniques
that can be used to analyze individual features of the data. These tech-
niques include standard survival models for modeling the time to game-
tocyte emergence and the duration of gametocytemia. The longitudinal
nonlinear gametocyte profile would typically be modeled using nonlinear
mixed effect models. These nonlinear models could then subsequently be
extended to accommodate the zero-inflation in the data, by changing the
x
underlying assumption around the distribution of the response variable.
However, it is important to note that these standard techniques do not
account for informative censoring. Failure to account for informative cen-
soring leads to bias in parameter estimates. Joint modeling techniques can
be used to account for informative censoring. The joint models applied in
this thesis combined the longitudinal nonlinear gametocyte densities and
the time to censoring due to either being lost-to-follow-up or treatment
failure.
The data analyzed in this thesis were collected from a series of clinical
trials conducted between 2002 and 2004 in Mozambique and the Mpumu-
langa province of South Africa. These trials were a part of the South East
African Combination Antimalarial Therapy (SEACAT) evaluation of the
phased introduction of combination anti-malarial therapy, nested in the
Lubombo Spatial Development Initiative. The aim of these studies was
primarily to measure the efficacy of sulfadoxine-pyrimethamine (SP) and
a combination of artesunate and sulfadoxine-pyrimethamine (ACT), in
eliminating asexual parasites in patients. The patients enrolled in these
studies had uncomplicated malaria1, at a time of increasing resistance
to sulfadoxine-pyrimethamine (SP) treatment. Blood samples were taken
from patients during the course of 6 weeks on days 0, 1, 2, 3, 7, 14, 21,
28 and 42. Analysis of these blood samples provided longitudinal mea-
surements for asexual parasite densities, gametocyte densities, sulfadoxine
drug concentrations and pyrimethamine drug concentrations.
The gametocyte data collected in this study were initially analyzed
using standard survival modeling techniques. Non-parametric Cox re-
gression models and parametric survival models were applied to the data
as part of this initial investigation. These models were used to investigate
the factors that affected the time to gametocyte emergence. Subsequently,
using the subset of the population that experienced gametocytemia, ac-
celerated failure time models were applied to investigate the factors that
affected the duration of gametocytemia. It is evident that the findings
from the aforementioned duration investigation would only be able to
provide valid duration estimates for patients who were detected to have
gametocytemia. This work was extended to allow for population level du-
ration estimates by incorporating the prevalence of gametocytemia into
the estimation of duration, for generic patients with specific covariate pat-
terns. The prevalence of gametocytemia was modeled using an underlying
binomial distribution. The delta method was subsequently used to derive
confidence intervals for the population level duration estimates that were
associated with specific covariate patterns. An investigation into the fac-
1Malaria is defined as uncomplicated when the signs and symptoms of malaria are present
but there are no clinical or laboratory signs to indicate severity or vital organ dysfunction.
xi
tors affecting the early withdrawal of patients from the study was also
conducted. Early exit from the study arose either through loss-to-follow-
up (LTFU) or through treatment failure.
The longitudinal gametocyte profile was modeled using joint model-
ing techniques. The resulting joint model used shared random effects to
combine a Weibull survival model, describing the cause-specific hazards of
patient exit from the study, with a nonlinear zero-adjusted gamma mixed
effect model for the longitudinal gametocyte profile. This model was used
to impute the incomplete gametocyte profiles, after adjusting for infor-
mative censoring. These imputed profiles were then used to estimate the
duration of gametocytemia.
It was found, in this thesis, that treatment had a very strong ef-
fect on the hazard of gametocyte emergence, density of gametocytes and
the duration of gametocytemia. Patients who received a combination
of sulfadoxine-pyrimethamine and artesunate were found to have signifi-
cantly lower hazards of gametocyte emergence, lower predicted durations
of gametocytemia and lower predicted longitudinal gametocyte densities




Malaria is the parasitic disease that affects the most humans. It is estimated
that 216 million episodes of malaria arose in 2016, with 194 million of these
episodes originating from the African region (WHO, 2017b). These episodes
are estimated to have resulted in 445 000 malaria related deaths, with Africa
contributing to 91% of these deaths.
The malaria species, Plasmodiumfalciparum, is responsible for the major-
ity of severe malaria cases and malaria related deaths. The asexual form of
the parasite is responsible for the signs and symptoms attributed to malaria
infection. Researchers who conduct malaria therapeutic efficacy studies are pri-
marily interested in the time to asexual parasite clearance and the efficacy of
treatment in curing patients, known as an adequate clinical and parasitological
response.
The basic lifecycle of the Plasmodiumfalciparum parasite, depicted graph-
ically by Michalakis and Renaud (2009), is illustrated in this thesis in Figure 1.
The basic lifecycle of the Plasmodiumfalciparum parasite can be summarized
as follows (Michalakis and Renaud, 2009, Barnes and White, 2005, Nacher et al.,
2002)
• Infected female mosquitoes bite a human host leading to the sporozoite
form of the parasite entering the host’s blood stream.
• Once in the host’s blood stream, sporozoites are transported to the liver
where they multiply asexually over a period of 5-9 days, which is referred
to as the “pre-erythrocytic” stage, before they become merozoites that
invade the red blood cells of the host.
• A repetitive asexual cycle begins and this leads to the host experiencing
chills and a fever, which are representative of clinical symptoms of malaria
infection. Subsequently male and female gametocytes are produced, with
mature gametocytes appearing in the host’s blood stream 10-12 days after
clinical symptoms appear.
• When a mosquito bites the host, gametocytes are transmitted into its
system. Once in the gut of the mosquito, the male and female gametocytes
fuse to form zygotes. These zygotes eventually give rise to sporozoites that
allow the lifecycle of the parasite to continue.
Research into the development of treatments that quickly and efficiently erad-
icate gametocytes is thus of critical public health importance as decreasing
1
gametocyte carriage reduces ongoing malaria transmission. This can especially
be advantageous in areas of increasing resistance to antimalarial treatment as
a decrease in gametocyte carriage can slow the spread of the resistance that
is threatening current malaria control and elimination efforts. It is thus essen-
tial that we improve our methods for the analysis of gametocyte data to better
define risk factors associated with gametocyte carriage.
Figure 1: Plasmodiumfalciparum life cycle as depicted by Michalakis and
Renaud (2009)
Host infectivity is defined as the probability of a mosquito becoming in-
fected after feeding off an infected individual. Host infectivity is the key driver
behind malaria transmission, though it is also important to note that there
are additional factors that affect transmission like vector (organisms that carry
pathogens from one host to another) characteristics, host susceptibility and cli-
matic conditions (Draper, 1953, Diebner et al., 2000, Killeen et al., 2006).
Historically very little attention has focused on the modeling of gametocytes.
Researchers commonly estimated the gametocyte density from the asexual par-
asite density. Examples of such methods include assuming a constant transition
rate between asexual and sexual parasites (Pongtavornpinyo, 2006) and the use
of models that rely on lagged values from asexual parasites (Ross et al., 2006).
Distiller et al. (2010) directly modeled the observed gametocyte profiles over
time, using nonlinear mixed effect models. In that paper a modified critical ex-
ponential model was applied as the underlying nonlinear function of the model.
2
Malaria intervention trials are generally not appropriately designed to mea-
sure the evolution of the gametocyte density in patients over time. This is
because the patient visitation schedules are based on the clinical and asexual
parasite response and do not coincide with the ideal times to observe the game-
tocyte life cycle. An additional hindrance to the observation of the gametocyte
density, over time, is censoring. In this study censoring occurred due to two
reasons. Firstly, a patient could be “rescued” and given an alternative treat-
ment due to either failure to clear asexual parasites or late treatment failure
(recurrence of asexual parasites due to recrudescence of the initial infection or
reinfection). Secondly patients could exit the study due to being lost-to-follow-
up. Rescuing patients from the study potentially leads to informative censoring.
Patients who were rescued could be expected to have asexual parasites in their
systems for prolonged periods of time. These asexual parasites would in turn be
expected to develop into gametocytes. As a result it could be hypothesized that
the prevalence of gametocytemia in patients who were rescued from the study
was higher than that of patients who remained in the study. The loss-to-follow-
up method of exit could potentially be either non-informative or informative
censoring. If it is assumed that patients who quickly experience a successful
clinical and parasitological outcome are more inclined to voluntarily exit the
study early, it would imply that these patients would have a lower prevalence
of gametocytemia as compared to the patients who remained in the study. It
might also be hypothesized that patients who were lost-to-follow-up were in poor
health and voluntarily exited the study to seek alternative treatment before they
were rescued from the study. Alternatively, the loss-to-follow-up might be due to
reasons completely unrelated to the study, which would imply non-informative
censoring. This will be investigated further in this thesis.
Censoring leads to truncated longitudinal gametocyte profiles. It can reason-
ably be assumed that the gametocyte profiles of patients who were rescued from
the study or who were lost-to-follow-up (assuming informative censoring) would
differ from the observed profiles of patients who were successfully treated and
observed to the end of the gametocyte cycle. Standard nonlinear mixed effects
models are typically used to impute incomplete longitudinal profiles. However,
these models do not account for informative censoring. Failure to account for
informative censoring in such situations leads to biased parameter estimates in
both survival and longitudinal models, which are fit to the data (Faucett and
Thomas, 1996).
Joint modeling techniques can be applied to account for informative censor-
ing. There are multiple approaches to joint models that have been documented.
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Examples of these approaches are Wang and Taylor (2001) who used the lon-
gitudinal response as a time dependent covariate in the proportional hazards
survival model. Lina et al. (2002) used a latent class model approach that in-
volved using a logistic model to determine the patient’s membership class and
then subsequently modeling the longitudinal and the survival processes, for a
given class, independently. Murawska et al. (2012) proposed a two-stage joint
model, under the Bayesian framework, which firstly modeled the longitudinal
process using a nonlinear mixed effect model and subsequently applied the Em-
pirical Bayes estimates of the subject-specific parameters as predictors in the
Cox proportional hazards model. Another approach, which will be expanded
upon for the purposes of this research, was proposed by Henderson et al. (2000).
This approach connected the longitudinal and survival processes together using
bivariate random effects. This approach was designed for a longitudinal process
that could be modeled using a linear mixed model and for a survival process
modeled using an intensity model with frailty. This approach will be extended in
this thesis to accommodate a nonlinear longitudinal process under the Bayesian
framework. The advantages of using the Bayesian framework to develop the
joint models used in this analysis are that asymptotic approximations of the
complicated likelihood functions, that will be developed, are avoided and the
framework is easily able to estimate complex functions of parameters arising
from the nonlinear nature of the fitted models (Ghosh et al., 2006).
4
2 Data overview
The data used in this analysis was from a series of randomized clinical trials
conducted between 2002 and 2004 in southern Mozambique and the Mpumu-
langa province of South Africa (Barnes et al., 2006, Allen et al., 2009). These
trials were a part of the South East African Combination Antimalarial Therapy
(SEACAT) Evaluation of the phased introduction of artemisinin-based combi-
nation anti-malarial therapy, nested within the Lubombo Spatial Development
Initiative. The aim of these studies was primarily to measure the efficacy of
two treatments, in eliminating asexual parasites in patients. The treatments
used were sulfadoxine-pyrimethamine (SP) and a combination of sulfadoxine-
pyrimethamine and artesunate (ACT). The patients enrolled in the study had
uncomplicated malaria, at a time of increasing resistance to sulfadoxine-pyrimethamine
(SP) treatment.
Over the period in that the study was conducted, malaria mortality rates had
been seen to be increasing despite there being a decrease in all cause mortality
rates (Snow et al., 2001, Korenromp et al., 2003). This increase was mainly
attributed to a rise in the resistance of Plasmodium falciparum parasites to
antimalarial treatment.
Historically, chloroquine was one of the most widely used treatments for
malaria. However, due to an increase in resistance, it became largely ineffective
in most malaria endemic countries (Trape, 2001). Sulfadoxine-pyrimethamine
became the successor to chloroquine and for some time became one of the
most widely used antimalarial drugs in the world. This was an ideal treat-
ment as it could be administered through a single dose as a tablet. Unfortu-
nately a resistance to this drug arose, thus limiting the effectiveness of the drug
(Babiker et al., 2005, Snow et al., 2001, Nosten et al., 2000, Targett et al., 2001).
Sulfadoxine-pyrimethamine is currently mostly used as a preventive treatment
in high risk groups such as pregnant women (in malaria endemic areas) and
infants (in areas of moderate to high malaria transmission) (WHO, 2015).
It is now recommended practice to administer combinations of two or more
drugs when treating malaria, as this approach is believed to reduce the devel-
opment of resistance to treatment. This is because it is unlikely that a parasite
would be able to mutate successfully against multiple drugs that would have
different mechanisms of action.
Artemisinin-based combination therapies are now the most recommended
treatment for Plasmodium falciparummalaria. The combination of artesunate
and sulfadoxine-pyrimethamine is currently one of the five options for the treat-
ment of uncomplicated malaria, in areas where sulfadoxine-pyrimethamine re-
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mains effective, that is recommended by the World Health Organization (WHO,
2015). The artesunate and sulfadoxine-pyrimethamine combination treatment is
currently the first line treatment in India and some Eastern Mediterranean coun-
tries (WHO, 2017b). Artemisinin-based combination therapies are renowned
for their ability to quickly reduce the number of parasites in a patient’s blood.
Artemisinin and its derivatives significantly reduce the number of asexual par-
asites in a patient’s blood in the first three days of treatment, subsequently the
drug administered in combination with artemisinin eliminates the remaining
parasites. Due to an expanded access to artemisinin-based combination thera-
pies, in malaria-endemic countries over the last 15 years, the global burden of
malaria has reduced (WHO, 2017a).
Over the period when this study was conducted, Plasmodium falciparum
had developed resistance to all classes of anti-malarial drugs with the possi-
ble exception of artemisinin derivatives (White, 2004, Pongtavornpinyo, 2006,
Barnes et al., 2006). As a result, artemisinin was a preferred drug to add to
a combination treatment. Unfortunately over the last few years artemisinin
resistance has been confirmed in the Greater Mekong Subregion, in countries
like Cambodia, the Lao Peoples Democratic Republic, Myanmar, Thailand and
Vietnam. In most cases, patients with artemisinin-resistant parasites are still
able to successfully clear their infection if the drug used in conjunction with the
artemisinin derivate is still effective in the geographical area. However, it has
been found that Plasmodium falciparum has become resistant to almost all
available antimalarial treatments in areas along the Cambodia-Thailand border
(WHO, 2013).
Patients who were considered for the analysis conducted in this thesis, did
not show signs of gametocytemia (the presence of gametocytes in the host’s
system) at entry into the study. These trials had a 42 day follow up period
with observations occurring on days 0, 1, 2, 3, 7, 14, 21, 28 and 42. On these
observation days, blood samples were taken from patients. Analysis of these
blood samples provided the following information on patients over the course of
the study
• Sulfadoxine drug concentrations over time,
• Pyrimethamine drug concentrations over time,
• Asexual parasite density over time,
• Gametocyte density over time.
It is important to note that, due to study guidelines, gametocyte densities were
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only recorded on days 0, 3, 7, 14, 21, 28 and 42. In total, 609 patients were
considered for this analysis.
A range of baseline covariates were collected from patients on entry into the
study, as shown in Table 1. These covariates were considered for their clinical
significance to the prevalence and duration of gametocytemia.
Table 1: Covariates used in this analysis.
Covariate Abbreviation
Baseline asexual parasite density per microliter, measured to the logarithm of base
10 (log10)
pzero
Indicator variable for the presence (1) or absence (0) of quintuple mutations mut5
Indicator variable for the treatment given to a patient, with a value of 0
for sulfadoxine-pyrimethamine treatment only (SP) and 1 for artesunate and
sulfadoxine-pyrimethamine combination treatment (ACT)
trt
Parasite reduction ratio at 24 hours ratio
Gender of patient, with males given a value of 1 and females given a value of 0 gender
Indicator variable for the presence (1) or absence (0) of moderate anaemia, with
patients who had a haemoglobin density of less than 11g/dL defined by the World
Health Organization (WHO) as having moderate anaemia
anaemia
Patient age in years, measured to the logarithm of base 2 (log2) lage
Treatment (trt) was used as a covariate because the implementation of arte-
sunate and sulfadoxine-pyrimethamine combination treatment (ACT) policies
was predicated on their more rapid asexual parasite clearance, higher cure rates
and reduced gametocyte carriage (White, 1997, Adjalley et al., 2011, Price et al.,
1996). Since gametocytes develop from asexual parasites, a treatment that
rapidly clears asexual parasites from a patient would be expected to have a low
gametocyte prevalence. The efficacy of asexual parasite clearance can be mea-
sured by the rate at that parasites are cleared. In this study, the percentage of
baseline asexual parasites cleared within 24 hrs (ratio) was used to measure the
rate of parasite clearance. In addition to the rate of clearance, the number of
baseline asexual parasites also plays a part in the prevalence of gametocytemia
as it would be expected that a high baseline asexual parasite density would
result in higher gametocyte prevalence. This assumption was applied in the
models by Pongtavornpinyo (2006) and Ross et al. (2006) that relied on asexual
parasite densities to estimate gametocyte densities in patients.
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This analysis was conducted in the presence of increasing resistance to SP
treatment in southern and eastern Africa. Pyrimethamine and sulfadoxine tar-
get the dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr) en-
zymes in the folate synthesis pathway of Plasmodium falciparum. When SP is
given to a patient, the combination of the pyrimethamine and sulfadoxine drugs
act in unison to disrupt folate synthesis and kill the Plasmodium falciparum
parasite. Resistance to SP arises due to point mutations that accumulate at
several sites in the dhfr and dhps genes. According to Roper et al. (2003), there
is a direct correlation between the number of pretreatment dhfr and dhps mu-
tations and the level of parasite resistance; with a high number of mutations
leading to an increase in treatment resistance. In this analysis, treatment resis-
tance was measured using a dichotomous variable (mut5) that takes a value of
1 if a patient has 5 mutations (3 dhfr and 2 dhps) and 0 if the patient has fewer
than 5 mutations. There were no infections in this study with greater than 5
mutations.
Researchers have found that the frequency of infection and density of asexual
parasites declines as the age of a population increases. This occurs primarily
in areas of moderate to high intensity transmission (e.g. in Mozambique) but
not in areas of low intensity transmission (e.g. Mpumulanga). This decline has
been attributed to partial immunity of the population due to repeated infections
(Despommier et al., 1994). The number of repeat infections that a patient gets,
can be considered as being proportional to the age of that patient specifically
in areas of more intense malaria transmission. Age can thus be considered as a
covariate that provides information about patient immunity. In this thesis the
logarithm to the base two of age was used. As a result, a one unit increase in
the logarithm to the base 2 of age can be interpreted as the doubling of age.
This approach seemed appropriate as the age distribution was skew to the right
with a long-tail. Taking the logarithm of distributions with such characteristics
narrows the range of a covariate and potentially leads to an acceleration in the
time to Bayesian model convergence. Patient gender was also included as a co-
variate in this analysis. Similarly to age, gender can harbor a latent relationship
of partial immunity to gametocytemia if associated with more frequent malaria
infections. In addition it allows for the population demographics to be included
in the analysis.
Authors like von Seidlein et al. (2001), Price et al. (1999) and Nacher et al.
(2002) found that the patients with low concentrations of haemoglobin, which
can be considered as the presence of anaemia, had a higher prevalence of gameto-
cytemia. In this analysis moderate anaemia was defined as having a haemoglobin
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concentration of less than 11g/dL. This definition is consistent with the guide-
lines outlined by the World Health Organization (WHO, 2011). Applying the
11g/dL cut-off level allowed for a balanced distribution of patients with anaemia,
across the various categories of covariates used in this analysis.
2.1 Treatment outcome
The simplified treatment outcomes from the study are shown in Table 2, along
with their respective definitions. The treatment failure classification used in this
analysis was a combination of the early treatment failure, recrudescence and
reinfection classifications outlined by the World Health Organization. These
classifications were combined for the purpose of this thesis in order to improve
the statistical power of the analysis.
Table 2: Simplified definition of treatment outcomes.
Outcome Definition
Success (Adequate Clinical and
Parasitological Response)
• Asexual parasites are cleared from the patient’s system
before day 7 with no recurrence
Failure • Asexual parasites fail to clear from the patient’s system
before day 7 (Early treatment failure)
• Asexual parasites clear before day 7 but they recur
during the course of the study (Recrudescence)
• Asexual parasites are cleared from the patient’s system
before day 7 and the patient contracts a new infection
during the course of the study (Reinfection)
LTFU (Loss-to-follow-up) • The patient is lost-to-follow-up during the course of the
study
The distribution of the patients included in the analysis, across the three
treatment outcome categories, is shown in Table 3. This table also provides a
comparison of the three treatment outcomes with respect to the baseline co-
variates. It can be seen that there was an overall 14.1 % treatment failure
rate (86 out of 609 patients). However, the overall treatment failure rate for
patients receiving a combination of artesunate and sulfadoxine-pyrimethamine
(ACT) treatment was only 3.3 % as compared to a 18.7% failure rate for patients
receiving sulfadoxine-pyrimethamine (SP) treatment. A Fisher’s Exact test re-
vealed that there was a strong association between the treatment administered
9
to a patient and treatment outcome. It can also be seen that there was a strong
association between treatment outcome and the presence or absence of the quin-
tuple mutations. There also appears to be an association between treatment
outcome and patient gender, with males being seen to have a higher treatment
failure rate as compared to females. The prevalence of moderate anaemia can be
seen to not have an association with treatment outcome. Kruskal-Wallis tests
revealed that all the distributions of the continuous covariates were significantly



















































































































































































































































































































































































































































































































































































































Figure 2 provides boxplots for the distribution of continuous covariates, an-
alyzed in this thesis, by treatment outcome. From this plot it can be seen that,
as compared to patients who achieved an adequate clinical and parasitological
response, patients who experienced treatment failure were
• generally younger
• had higher baseline asexual parasite densities










































































Figure 2: Boxplots of continuous covariates by treatment outcome
The probability that a patient survived without experiencing either treat-
ment failure or loss-to-follow-up was assessed graphically using Kaplan-Meier
survival plots shown in Figure 3. In the derivation of these plots patients who
were lost-to-follow-up were conservatively combined with patients who experi-
enced treatment failure. It is evident that the highest survival rates are asso-
ciated with female patients, patients receiving a combination of artesunate and
12
sulfadoxine-pyrimethamine (ACT) treatment, patients with less than 5 muta-
tions and patients with a haemoglobin density greater than 11g/dL. It is im-
portant to note that there was a marginal difference between the survival prob-
abilities of patients receiving sulfadoxine-pyrimethamine treatment only (SP)
and patients receiving artesunate and sulfadoxine-pyrimethamine combination
treatment (ACT). The reason for this weak effect is shown in Figure 4 and
Figure 5. These figures show the Kaplan-Meier survival plots when treatment








































































































0 7 14 21 28 42
Figure 3: Kaplan-Meier survival plots, by categorical covariates, when treat-
ment failure and loss-to-follow-up were combined and considered as the event
of interest
In deriving Figure 4, loss-to-follow-up events were considered as censored
observations while in Figure 5 treatment failures were considered as censored
observations. It is evident that a patient receiving sulfadoxine-pyrimethamine
(SP) treatment is more likely to experience treatment failure and less likely
to be lost-to-follow-up, as compared to a patient receiving a combination of
artesunate and sulfadoxine-pyrimethamine (ACT) treatment. It is interesting
to note that treatment appears to be the only categorical covariate that has an
13
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Figure 4: Kaplan-Meier survival plots, by categorical covariates, when treatment
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Figure 5: Kaplan-Meier survival plots, by categorical covariates, when loss-to-
follow-up was considered as the event of interest
2.2 Gametocyte prevalence
The association between gametocyte prevalence and the covariates considered in
this analysis, is summarized in Table 4. It can be seen that 83% of patients who
received a combination of artesunate and sulfadoxine-pyrimethamine (ACT)
treatment did not develop any gametocytes. In comparison only 51% of pa-
tients receiving sulfadoxine-pyrimethamine (SP) treatment did not develop any
gametocytes. A Fisher’s Exact test reveals that there is a strong association
between treatment and the prevalence of gametocytemia. It is also shown that
mutation prevalence (mut5) and age (lage) do not have any association with
the prevalence of gametocytemia. It can be seen that patient gender (gender)
and the prevalence of moderate anaemia (anaemia) appear to have some asso-
ciation with gametocyte prevalence. Male patients can be seen to have a higher
prevalence of gametocytemia as compared to females. In addition, patients with
moderate anaemia have a higher prevalence of gametocytemia as compared to
patients with a haemoglobin density greater than 11g/dL. Table 4 also reveals
15
that the prevalence of gametocytemia is strongly associated with treatment out-








































































































































































































































































































































































































































































































































































































Figure 6 provides boxplots for the distribution of continuous covariates, by
the prevalence of gametocytemia. This figure reveals that patients with a high
baseline asexual parasite density generally exhibit gametocytemia more often
than patients with a low baseline asexual parasite density. Figure 6 also reveals
that patients with a low first 24 hour parasite reduction ratio are more likely
to experience gametocytemia as compared to patients with a high first 24 hour
parasite reduction ratio. It is evident from this figure that patient age does
not appear to have an association with the prevalence of gametocytemia as the















































































Figure 6: Boxplots for the continuous covariates, by gametocyte prevalence
Table 5 shows that gametocytes were present in only 538 of the 3771 obser-
vations recorded during the study, with these observations arising from only 239
patients (Table 6). Table 5 reveals that the incidence rate for gametocytemia
peaks between days 7 and 21. This table also highlights that there is a nonlinear
relationship between gametocyte prevalence and time.
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Table 5: Gametocyte presence over time.
Day Gametocytes absent Gametocytes present Total observations Incidence rate
0 609 0 609 0.000
3 524 58 582 0.100
7 427 141 568 0.248
14 398 136 534 0.255
21 388 103 491 0.210
28 413 78 491 0.159
42 474 22 496 0.044
Total 3233 538 3771 0.143
Table 6: Distribution of the number of gametocytes observed per patient during
the study.










Gametocyte density measurements were taken microscopically, by counting the
number of observed gametocytes on thick blood smears contrasted against 1,000
leukocytes, assuming 8,000 leukocytes per microlitre (µL). The implication of
the data collection method was that the lowest detectable density was 8 per
µL. For the purposes of this analysis values below this limit were considered as
being zero. In addition the response variable that will be considered for analysis
in this investigation, will be the logarithm to the base two of the observed
number of gametocytes. Taking the logarithm of a long-tailed measurement is
a commonly applied method of analysis, as it improves the symmetry of the
19
underlying distribution that generally leads to an acceleration in the time to
Bayesian model convergence. The implication is that a one unit increase in the
logarithm to the base two values of the gametocyte density will be equivalent





































Figure 7: Distribution of log2 gametocyte density for the full dataset and the
reduced dataset, where only observations with gametocytes recorded were con-
sidered
Figure 7 shows the distribution of log2 gametocytes for all patients consid-
ered in this analysis. It can be seen that the data is zero-inflated as over 80%
of the observations had zero values. Such data can be analyzed using a mix-
ture distribution that models the prevalence of gametocytemia using a logistic
model and assigns a continuous distribution to the logged nonzero gametocyte
measurements.
Figure 7 indicates that the distribution of the logged nonzero gametocyte
measurements are still right-skewed. The fitdistrplus package (Delignette-
Muller et al., 2014) in R Core Team (2015) was applied to determine the dis-
tribution of the nonzero component of the gametocyte data, using graphical
assessment. Two distributions, the log-normal distribution and the gamma dis-
tribution, were considered as candidates. These distributions were considered
because they are able to accommodate long-tailed continuous data. Figure 8
provides a graphical fit of these two distributions to the nonzero component of
the data. It can be seen from this figure that there is very little difference, with
20
regards to fit, between the two distributions. Akaike’s Information Criterion
(AIC) and Bayesian Information Criterion (BIC) statistics were used to assess
the goodness of fit of these distributions. The results of these tests are shown in
Table 7. It can be seen that the gamma distribution is marginally better than
the log-normal distribution. As a result the gamma distribution was applied to
the logged nonzero gametocyte measurements, when a mixture distribution was
used as a means to handle the zero-inflation in the data.








































































































































































































































Figure 8: Graphical goodness of fit tests for the log-normal and gamma distri-
butions, to the non-zero gametocyte densities




Figure 9 illustrates the mean profiles across the categorical covariates consid-
ered in this analysis. It can been seen that the mean profile for patients receiving
21
a combination of artesunate and sulfadoxine-pyrimethamine (ACT) treatment
was considerably lower than for those receiving sulfadoxine-pyrimethamine (SP)
treatment only. It can also be seen that the gametocyte density profile over time
across all covariates follows a non-linear trajectory, which peaks between days 7
and 21. The implication of these findings is that a nonlinear mixed effect model
would need to be applied during the course of this investigation.
In the next section the results of an analysis into the time-to-event processes
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Figure 9: Gametocyte mean profiles by categorical covariates
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3 Survival Models
The aim of many clinical trials is to investigate the time until a predefined
event occurs and to determine significant risk factors that have an impact on
this observed time. In the context of this analysis, the time-to-event processes
can be considered as the time to early exit from the study, time to gametocyte
emergence or time to gametocyte clearance. Throughout the remainder of this
section the time to early exit from the study will be referred to as the event of
interest.
Historically survival analysis was used to estimate the probability of sur-
vival. Popular non-parametric estimators of the probability of survival are the
Kaplan-Meier (Kaplan and Meier, 1958) and the Nelson-Aalen (Aalen, 1976)
estimators. Another area of interest is the statistical modeling of survival data.
This approach allows for the impact of multiple risk factors on the survival
process to be analyzed simultaneously.
In survival data analysis, the time-to-event (T ) random variable is defined
as strictly positive with a range of (0,∞). As a result this random variable
usually has a positively skew distribution. This skewness makes the assumption
of normality, required for certain statistical methods, invalid.
A key characteristic of survival data is censoring. Censoring occurs when
the event of interest is not observed for an individual. An example of censoring
is when the study comes to an end before the event of interest is observed.
Censoring results in incomplete data, as not all times to the event of interest are
recorded for individuals in the study. Failure to account for this censoring results
in biased estimates. Inferences from incomplete data are also more sensitive to
the misspecification of the distribution of survival times as compared to complete
data (Rizopoulos, 2012). As a result, the use of standard statistical methods on
survival data is unreasonable.
There are several types of censoring, namely
• Right censoring - The event of interest is only known to have occurred
after a given timepoint
• Left censoring - The event of interest is only known to have occurred before
a given timepoint
• Interval censoring - The event of interest is only known to have occurred
between two specified timepoints. This type of censoring is thus a combi-
nation of left and right censoring
In the presence of censoring, survival data consists of two components. These
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components are the duration that an individual was at risk in a study (T ) and an
indicator of whether the event of interest occurred (δ). The indicator component
takes on a value of 1 if the event of interest occurred and 0 otherwise.
When accounting for censoring it is important to consider whether the prob-
ability of censoring depends on the time-to-event process. Informative censoring
occurs when the reasons for a patient being censored are related to the time-to-
event process. An example of informative censoring is when a patient withdraws
from a treatment efficacy study because their health deteriorates and they seek
alternative treatment. On the other hand non-informative censoring occurs
when the reasons for censoring are not related to the time-to-event process. An
implication of non-informative censoring is that the patients who remain in the
study have the same risk of hazard as compared to the censored lives.
An area of interest in this analysis is the measurement of the duration of
gametocytemia. This involves observing a patient from the time they develop
gametocytemia, to the time of gametocyte clearance. Considering only patients
who developed gametocytemia; right censoring occurs when either the study
ends or a patient exits the study before gametocyte clearance has occurred. In
this study, early exit from the study occurs due to either loss-to-follow-up or
treatment failure. In this scenario, early exit from the study can be viewed as
informative censoring. This is explained by discussing the impact of censoring
due to treatment failure and loss-to-follow-up outcomes separately.
Patients who experience treatment failure are rescued from the study and
given alternative treatment. These patients can be expected to have asexual
parasites in their systems for prolonged periods of time. Assuming that there is a
direct correlation between the asexual parasite and the sexual parasite densities,
it can be hypothesized that the prevalence of gametocytemia in patients who
are rescued from the study is higher than that of patients who remain in the
study. This would imply that early exit from the study due to treatment failure
is a form of informative censoring.
Patients who are lost-to-follow-up, can be assumed have quickly experienced
a successful clinical and parasitological outcome. These patients would thus
be more inclined to voluntarily exit the study early, which would imply that
these patients would have a lower prevalence of gametocytemia as compared to
the patients who remain in the study. Assuming that this hypothesis is correct,
loss-to-follow-up would be a form of informative censoring. Additionally, assum-
ing that the hypothesis regarding the health status of patients lost-to-follow-up
holds, treatment failure and loss-to-follow-up would potentially be competing
risks of early exit from the study. However, it is important to note that the rea-
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sons for loss-to-follow-up could potentially be completely unrelated to the study
(e.g. accidental death). In such a scenario loss-to-follow-up would be considered
as random censoring. This will be investigated further in this chapter.
This section will proceed as follows: firstly an overview of the methodology
used in survival analysis will be provided. The techniques that will be discussed,
will then be applied to the analysis of the time to gametocyte emergence, time
to gametocyte clearance and the time to early exit from the study.
3.1 Overview of survival analysis functions
Several survival functions are introduced in this section. These functions are
used to develop the methodology behind the survival modeling techniques im-
plemented in this analysis. The notation and theory used in this section is
derived from Collett (1994) and Rizopoulos (2012). The event of interest will
be considered as the time to early exit from the study.
The random variable for the time to early exit from the study is given as
T , with t being the observed time. T is considered as being a non-negative
continuous variable. This variable is assumed to have a probability density
function denoted by f(t). The resulting cumulative distribution function F (t)
is defined as the probability of exit occurring before time t and it is defined as




On the other hand the survival function S(t) is the probability of exit not
occurring by time t. The survival function is given as




The survival function is a non-increasing function, over time, which is bounded
over the range [0, 1] with the probability of survival at time 0 given as 1.
The hazard function gives the instantaneous risk of exit over the time interval
[t, t+ δt), given that the individual survived (exit did not occur) to time t. The








with h(t)δt being the approximate probability that the event of interest occurs
in the small interval [t, t + δt). The relationship between the hazard function








where H(t) is the cumulative hazard function.
The duration until a patient exits the study can be estimated by taking the





3.2 Modeling the hazard function
Statistical modeling of the hazard function allows for the impact of multiple
risk factors on the survival process to be simultaneously assessed. The resulting
models allow for the derivation of individual hazard functions for patients, based
on their covariate patterns. Insights from these models can provide guidance
to clinicians with regards to the appropriateness of treatment protocols and
medical intervention strategies. In this section semi-parametric and parametric
hazard models will be discussed.
3.2.1 Semi-parametric proportional hazards models
Given that n patients are observed in a treatment efficacy study, with the hazard
of exit for the ith patient depending on a set of p observed covariates xTi =
(xi1, . . . , xip), the hazard function under the Cox proportional hazards model
framework (Cox, 1972) is described as
hi(t) = h0(t) exp(x
T
i β), (6)
where β is a p dimensional vector of fixed effect coefficients and h0(t) is the
baseline hazard at time t. The baseline hazard is the underlying hazard of exit









where hi(t)h0(t) is defined as the hazard ratio that represents the relative change
in the hazard of exit due to the predictor variables in the fitted model. The
logarithm of the hazard ratio is seen to have linear relationship with the predic-
tor variables in the fitted model. The model is semi-parametric in nature as its
coefficients (β) can be estimated without needing a distributional assumption
for h0(t).
Considering the case where a single continuous predictor variable is included
in the fitted model, eβ represents a relative change in the hazard of exit due to
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a one unit increase in the predictor variable. In the case of a binary indicator
variable, specifying the presence (1) or absence (0) of the predictor variable, eβ
represents the relative change in the hazard of exit due to the presence of the
predictor variable. When eβ is greater than 1, it implies that there is a relative
increase in the hazard of exit occurring.
A key assumption of the Cox proportional hazards model is that any change
in the hazard ratio, due to the effect of a particular predictor variable, is con-
stant over time. This is known as the proportional hazards assumption. To
illustrate this, consider the SP and ACT treatments defined in Chapter 1. The
proportional hazard assumption implies that the following relationship is con-
stant over time
hACT (t) = hSP (t)ψ, (8)
where ψ is the ratio of the hazards of exit for a patient receiving ACT treatment
relative to SP treatment. This result implies that
SACT (t) = [SSP (t)]
ψ. (9)
The coefficients of the proportional hazards model, given in equation 6, can be
estimated using the method of maximum partial likelihood. In the absence of
ties, multiple exits occurring at the same time, the partial likelihood function










with δi being an indicator variable that has a value of 0 if the i
th survival time
is right censored and 1 otherwise; R(t(i)) is the risk set at time ti. The resulting












Numerical methods like the Newton-Raphson procedure (Lange, 2004) can
be used to obtain maximum likelihood estimates for the β coefficients given in
equation 11.
The appropriateness of applying the Cox proportional hazards model, to a
dataset, depends on the validity of the proportional hazards assumption. This
assumption should thus be validated before fitting the Cox model. In this thesis
a graphical assessment of the validity of the proportional hazards assumption
will be employed. A plot of the cumulative hazard function against time can be
used to test this assumption for each covariate used. This can be illustrated by
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considering a model with only one covariate. The cumulative hazard function











logHi(t) = βxi + logH0(t)
(12)
This can be rearranged to give
βxi = logHi(t)− logH0(t).
It is evident that the difference between the log-cumulative hazard plots of
patients with different covariate patterns does not depend on time. Given two
patients with covariates values of x and x+ 1, the difference between their log
cumulative plots will be constant over time with a value of β.
3.2.2 Parametric proportional hazards models
The Cox proportional hazards model does not assume a probability distribu-
tion for the survival times. As a result the baseline hazard is unspecified, with
the shape of the function defined by the underlying data used in the analysis.
This leads to a flexible hazard function that can be applied in a wide range of
scenarios. Models that assign a distribution to the baseline hazard function are
called parametric proportional hazards models. Inferences from these models
are more precise as compared to those from the Cox model. In addition the
standard errors from these models are smaller than those from the Cox model.
Two popular parametric proportional hazards models are the Weibull and the
exponential models. These models assume that the survival times (t), defined
over the range 0 ≤ t <∞, follow Weibull and exponential distributions respec-
tively. The underlying survival functions for these parametric models are given
in Table 8.
Table 8: Exponential and Weibull survival functions.
Function Exponential Weibull




The exponential parametric model assumes that the baseline hazard function
is constant over time. This implies that once the study has began, the hazard
of exit remains constant over time.
The Weibull parametric model allows the baseline hazard function to depend
on two strictly positive parameters λ and ρ, where λ is the scale parameter and
ρ is the shape parameter. The baseline hazard function can be seen to simplify
to that of the exponential model when ρ = 1. In the case when ρ 6= 1, the
hazard function is monotonically increasing (when ρ > 1) or decreasing (when
ρ < 1) over time.
Equation 6 can be expanded to assume that survival times of the n patients
observed in the study, follow a Weibull distribution. As a result the baseline
hazard function can be defined as
h0(t) = λρt
ρ−1.
The definition of the proportional hazards model can be extended as follows
hi(t) = h0(t) exp(x
T
i β)
= λρtρ−1 exp(xTi β).
(13)
It is evident that hi(t) also follows a Weibull distribution with scale parameter
λ exp(xTi β) and shape parameter ρ. This result verifies that the proportional
hazards property is upheld for the Weibull distribution. It follows that the
resulting survival function is given as
Si(ti) = exp{−λtρi exp(x
T
i β)}.
The likelihood function for the Weibull proportional hazards model is given as















where δi is an indicator variable having a value of 1 if exit occurs and 0 otherwise.
The parameters β, ρ and λ are estimated by maximizing the logarithm of the
likelihood function, l(β, ρ, λ), which is given as











The Newton-Raphson algorithm can be used to maximize the log-likelihood
function given in Equation 15. Setting ρ = 1, gives the corresponding result for
the exponential model.
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3.2.3 Accelerated failure time models
Parametric and semi-parametric proportional hazards models depend on the va-
lidity of the proportional hazards assumption. In situations where this assump-
tion is not valid, accelerated failure times (AFT) models can be used. AFT
models are able to accommodate a larger pool of survival time distributions as
compared to the proportional hazards models. In this section the general form
of the AFT model will be provided along with the specific formulations for the
exponential and Weibull models.
Collett (1994) provides the following log-linear representation of the AFT
models
log Ti = α0 + α1xi1 + α2xi2 + · · ·+ αpxip + σεi




where Ti is the time to early exit for the i
th patient, xij is the j
th covariate
recorded for the ith patient, α1, . . . , αp are unknown coefficients, α0 is the value
of log Ti when all covariates are equal to 0 (baseline value of log Ti), σ is the
scale parameter and εi is the residual error that is assumed to follow a particular
probability distribution. The survival function for the ith individual is given as
Si(t) = Pr[Ti ≥ t]
= Pr[e(α0+x
T
i α+σεi) ≥ t]
= Pr[e(α0+σεi) × ex
T
i α ≥ t]








where φ = ex
T
i α and S0(.) is the baseline survival function. From Equation 17
it can be seen that the survival probability of the ith individual at time t is
equivalent to the baseline survival probability at time tφ−1. This relationship
is referred to as the accelerated failure time property that defines this class of
models. The factor φ is known as the acceleration factor. If φ < 1 then the time
to early exit from the study is accelerated. If φ > 1 then the time to early exit
from the study is decelerated. The general AFT hazard function can be derived
from Equation 17 as follows
Si(t) = S0(te
−xTi α)















The Weibull and exponential models possess both the accelerated failure
time and proportional hazards properties. The Weibull model will be used to
illustrate this. Consider n survival times that are assumed to follow a Weibull
distribution, with a baseline hazard function of
h0(t) = λρt
ρ−1.














Under the proportional hazards (PH) framework, the hazard function for the







where β1, . . . , βp are unknown coefficients estimated under the PH framework.
The β coefficients (estimated under for the PH model) can be equated to the α
coefficients (estimated under the AFT framework), by using the relationship
β = −αρ.
The Weibull model can thus be seen to possess both the proportional hazard
and the accelerated failure time properties. This also holds for the exponential
model, as it is just a special case of the Weibull model with ρ = 1.
The Weibull and exponential models are used to model monotonically in-
creasing or decreasing hazard functions. If the hazard function is not mono-
tonically increasing or decreasing over time then the log-logistic, log-normal
and generalized-gamma models can be used. The density, survival and hazard






























































where Φ(z) is the standard normal cumulative distribution function.
The exponential, log-normal and Weibull distributions are all special cases of
the generalized-gamma distribution (Collett, 1994). As a result the generalized-
gamma distribution can be used to test for the functional form of a standard
parametric survival model. The probability density function of the generalized-





for 0 ≤ t < ∞, where λ > 0 is the scale parameter; γ > 0 and θ > 0 are shape





The corresponding survival function is given as
S(t) = 1− I{γ, (λt)θ},
where I{γ, (λt)θ} is the incomplete gamma function given as










Prentice (1974) highlighted that the above parametrization of the generalized-
gamma distribution led to log-likelihood equations that did not always have
solutions. He thus proposed an alternative parametrization of this distribu-
tion. This alternative approach was applied in this thesis. The notation used
to describe this approach is consistent with the notation used in the flexsurv
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package (Jackson, 2016) of the R statistical program (R Core Team, 2015). The

















1− I(γ, u) if q > 0
1− Φ(z) if q = 0

























I(γ,u) if q < 0
,
where
• I(γ, u) is the incomplete gamma function
• Φ is the standard normal cumulative distribution
• u = γe(|q|z)
• z = sign(q){log t−µ}σ
• γ = |q|−2
The special cases of the generalized-gamma distribution are outlined in Table
9.
Table 9: Special cases of the generalized-gamma distribution.
Distribution Parameterization
Exponential q = 1 and σ = 1
Gamma σ = |q|
Log-Normal q = 0
Weibull q = 1
3.2.4 Model checking
Once a survival model has been fit to a dataset it is important to assess the
adequacy of the model fit. An analysis of the Cox-Snell residuals, from the
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fitted model, can be used for this purpose. The Cox-Snell residual for the
ith individual, rCi, is defined as the estimated value of the cumulative hazard
function for the ith observation at time ti (Collett, 1994). The Cox-Snell residual
is thus given as
rCi = Ĥi(ti)
= − log Ŝ(ti).
(24)
The Cox-Snell residuals follow a unit exponential distribution. A fitted model
is deemed adequate if a plot of the cumulative hazard of the Cox-Snell residuals
against the Cox-Snell residuals, produces a straight line through the origin with
a gradient of 1. If these conditions are not met, the fitted model is deemed
inappropriate and an alternative model is fit to the data.
Martingale (rMi) and deviance residuals (rDi) are additional residuals that
can used to determine model adequacy. Martingale residuals are defined as
rMi = δi − Ĥi(ti)
= δi − rCi,
(25)
where δi is an indicator value taking a value of 1 if the event of interest occurs
and 0 otherwise. These residuals are derived using martingale methods outlined
in Fleming and Harrington (1991). Martingale residuals have a mean of 0 and a
range of (−∞ , 1], with censored observations having negative residuals. These
residuals can be used to assess the validity of the functional form of covariates,
in addition they can be used to identify outliers. A key feature of martingale
residuals is that they are asymmetric, which makes them difficult to interpret.
Therneau et al. (1990) introduced deviance residuals that are a transformation
of martingale residuals. These residuals closely resemble standardized residuals
from linear regression in that they are symmetric, have a mean of 0 and a
standard deviation of 1. Deviance residuals are defined as
rDi = sign(rMi)
√
−2[rMi + δi log(δi − rMi)]. (26)
These residuals are negative when the observed times to event are smaller than
expected. If a model is adequate, a plot of deviance residuals against fitted
values would not have a systematic trend. Since deviance residuals are derived
from martingale residuals, it was deemed sufficient to only consider Cox-Snell
and deviance residuals when assessing model adequacy.
3.2.5 Model selection
Model selection involves the comparison of multiple alternative models using
various tests. The deviance test is an example of a test that can be applied. It
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is used when the models being compared are nested, that is when one model con-
tains explanatory variables that are a subset of these in the alternative model.
The deviance test statistic is defined as the difference between the fitted log-
likelihood functions of the models being compared. The derived maximum like-
lihood estimates, from the individual model fits, are used as the parameters
for the respective models in the deviance test. To illustrate this, consider two
nested models m1 and m2. Model m1 consists of p explanatory variables, while
m2 consists of p+ q explanatory variables. The maximized log-likelihood func-
tions for the models are given as l̂1 and l̂2. The deviance statistic is defined
as
D = −2{log l̂1 − log l̂2}, (27)
with the distribution of D being approximately chi-squared with degrees of
freedom equal to q under the null hypothesis that the additional q parameters
are equal to 0.
In the event that two non-nested models are being compared, the AIC
(Akaike, 1974) statistic can be computed per model. The model with the lower
AIC statistic is considered as the best model. The AIC statistic for m1 is defined
as
AIC1 = −2{log l̂1}+ 2p. (28)
The AIC statistic is designed to penalize complex models as each additional
parameter incurs a penalty on the statistic.
3.3 Competing Risks Models
The discussion around survival analysis has focused on the time until a single
predefined event, that is time to early exit from the study. As previously stated,
early exit from the study can arise either through treatment failure or through
loss-to-follow-up. In reality researchers who conduct treatment efficacy studies
are mainly interested in the hazard of treatment failure, being lost-to-follow-up
prevents researchers from observing treatment failure. As a result loss-to-follow-
up can be considered as a competing risk to treatment failure, as it hinders
the observation of treatment failure. When analyzing competing risk data a
researcher has the choice of either accounting for the competing event or ignoring
it. Pintilie (2007) highlighted that ignoring the competing risk can be beneficial
as long as the interpretation of the results from the analysis is correct. The
decision regarding the treatment of competing risks is driven by the research
question on hand. In this study a researcher could seek to answer any one of
the following questions:
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1. How many more patients experienced treatment failure after taking a com-
bination of artesunate and sulfadoxine-pyrimethamine treatment (ACT)
as compared to sulfadoxine-pyrimethamine (SP) treatment only?
2. Is the rate of treatment failure different between the ACT and SP treat-
ments?
Given that a researcher is attempting to solve the first question, consideration
must be made for the number of patients who were lost-to-follow-up as they
reduce the number of treatment failures that could have been observed. A
Fine-Gray competing risk models that makes use of the sub-distribution hazard
function (Fine and Gray, 1999, Lau et al., 2009), can be used in this situation.
When attention is turned to the second question, the presence of a competing
risk is not desirable, thus it is ignored in the analysis. The cause-specific haz-
ard model (Kalbfleisch and Prentice, 2002), would be applied in this scenario.
The key difference between the cause-specific and the Fine-Gray model is the
definition of the hazard function for the two models.
Given that the random variable for the time to early exit from study is









It can be assumed that early exit from the study may occur due to a set of m
distinct causes that are indexed by j ∈ {1, 2, . . . ,m}, with J being a random
variable that indicates the specific cause of exit. Based on this, the cause-specific








The cause-specific hazard function can be interpreted as the approximate prob-
ability that an individual exits the study in a small interval [t, t + δt) due to
the jth cause of exit. The overall hazard function, given in equation 29, can be
defined as the sum of the m distinct cause-specific hazard functions through the





The Fine-Gray model would look at the instantaneous risk of exit from the
jth event in patients who have either not exited or who have exited due to any of
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The definition of the sub-distribution hazard function incorporates the use of
an “unnatural” risk set, which contains patients who are still in the study and
patients who exited the study due to reasons other than j. In order to account
for this mixture of lives, weights are applied in the sub-distribution likelihood
function to distinguish between patients who are still in the study and those that
exited due to reasons other than the jth cause. Details around the application
of these weights can be found in the paper by Fine and Gray (1999).
Based on the characteristics of these models, Lau et al. (2009) proposed that
the cause-specific model should be used to answer epidemiological questions
around the causes of diseases. These authors also proposed that the Fine-Gray
model should be used for the development of predictive models for clinical use.
This was because the Fine-Gray model allows for the direct modeling of the
effect of covariates on the incidence of a particular event, while accounting for
competing events.
One of the aims of this thesis is the imputation of incomplete gametocyte
profiles in the presence of censoring, which arises due to exit from the study
either from loss-to-follow-up or treatment failure. The hazard rates of these
two causes of exit are expected to provide information that will be used in the
imputation of the incomplete gametocyte profiles. Since interest is in the hazard
rates of the two causes of exit, only cause-specific hazard models were considered
in this analysis. These models will be expanded upon for the remainder of this
section.
3.3.1 Cause-specific hazard model















It can be seen that the resulting survival function, interpreted as the probability






where H(t) is the cumulative hazard function.
The cause-specific probability density of exit, at time t, is the unconditional
risk that a patient exits the study due to the jth cause of exit at time t. This
density is defined as
fj(t) = lim
δt→0





The overall probability density function of exit is given by applying the law of





The likelihood function for the cause-specific hazard model can be derived
from equations 31 and 33. Given that n patients are observed in the study and
that the following data is recorded for the ith patient
• ti the observed exit time
• δi an indicator variable with a value of 1 if exit occurred
• ji the cause of exit, with ji ∈ {1, 2, . . . ,m} when an exit occurred and
undefined otherwise
• xi covariates recorded for the ith patient.
















The defined likelihood is derived by considering the following probability con-
tributions
• The probability contribution of a patient who is censored at time ti, thus
contributing a probability of Si(ti)
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• The probability contribution of a patient who has exited at time ti due to
cause j, thus contributing a probability of hji(ti)Si(ti)
An indicator variable, δij that has a value of 1 when the i
th patient exits due to
the jth cause and 0 otherwise, can be introduced into equation 34. Given the
restriction that a patient can exit from only one cause (if multiple causes occur
















The overall likelihood function can be seen to be the product of m likelihood
functions derived for each of the causes of exit. The implication is that hj(t) can
be maximized using separate likelihood functions. Additionally, when consider-
ing a specific cause of exit, the likelihood for that cause is exactly the same as
the likelihood obtained if the other m− 1 causes of exit we treated as censored
observations. As a result the m likelihood functions can be solved using any of
the modeling methods previously outlined in this chapter.
3.4 Interval censoring
The gametocyte data used in this analysis was collected over a 42 day follow
up period with observations occurring on days 0, 3, 7, 14, 21, 28 and 42. On
these observation days, blood samples were taken from patients. Subsequently
gametocyte density measurements were taken microscopically, by counting the
number of observed gametocytes on thick blood smears contrasted against 1,000
leukocytes, assuming 8,000 leukocytes per microlitre (µL). Due to the design of
the study, it is evident that interval censoring would be expected to arise. This
would affect both the time to gametocyte emergence and time to gametocyte
clearance survival analyses.
When considering a time to gametocyte emergence analysis, a patient can be
observed to not have gametocytes at entry into the study then subsequently on
day 3 it can be found that gametocytes have developed in the patient’s blood.
It is clear that the gametocytes would have developed at some point between
day 0 and 3. This is an example of interval censoring.
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Table 10 reveals the number of patients who experienced gametocytemia and
the respective periods when gametocytemia first occurred. It is evident that ga-
metocytes first emerged within the first 7 days of follow up, in 70% of the
patients who experienced gametocytemia. This is the period when the intervals
between observation days was the shortest. As a result it can be assumed that
interval censoring would have a small impact on the time to gametocyte emer-
gence analysis. As a result interval censoring techniques were not considered for
that analysis.
Table 10: Number of patients who experienced gametocytemia, by period in
which gametocytemia occurred.
Interval (0 , 3] (3 , 7] (7 , 14] (14 , 21] (21 , 28] (28 , 42] Total
Number of patients 58 110 42 14 13 2 239
Table 11 reveals that 89% of the gametocyte clearances, in patients who
were able to clear their gametocyte infection during the course of the study,
were observed after day 7. This coincides with the period that had the longest
intervals between observation days. It is clear that interval censoring would be
expected to have an impact on the time to gametocyte clearance analysis.
Table 11: Number of patients who cleared gametocytemia, by period when
clearance occurred.
Interval (0 , 3] (3 , 7] (7 , 14] (14 , 21] (21 , 28] (28 , 42] Total
Number of patients 0 22 37 42 38 56 195
Authors like Huang (1996), Kooperberg and Clarkson (1997), Younes and
Lachin (1997) and Lindsey and Ryan (1998) developed non-parametric ap-
proaches to apply when analyzing interval censored data. Work has also gone
into the parametric modeling of interval censored data (Samuelson and Kongerud,
1994, Klein and Moeschberger, 2005). Lindsey (1998) highlighted that since
parametric models naturally apply smoothing to the observed data, as these
models use information from adjacent points as part of their estimation proce-
dure, interval censoring would be expected to have less of an impact on para-
metric models as compared to non-parametric models.
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In this chapter it will be assumed that gametocyte clearance occurs in the
middle of an interval. Subsequently the midpoint of this interval would be used
as a point estimate for the gametocyte clearance time. It was shown by Lindsey
(1998) that this approach can provide good results for the estimation of model
parameters. However, this approach is not always reliable.
It is acknowledged that the use of the midpoint is a simplistic approach to ap-
ply when analyzing gametocyte clearance data. However, it is important to note
that the main aim of this thesis is the imputation of the incomplete gametocyte
profile in the presence of informative censoring. These completed profiles would
provide estimates for all missing data, including missing data arising in-between
the predefined study observation days. Subsequently the complete profiles can
be used to conduct an analysis into the time to gametocyte clearance. The use
of these imputed profiles would mitigate the effect of interval censoring on the
resulting analysis. The results of the time to gametocyte clearance analysis,
conducted in this chapter, will be used for comparative purposes. These results
will be compared with the results of a survival analysis conducted using imputed
gametocyte data.
3.5 Model fitting results
The methodology around survival analysis, which has previously been discussed,
was applied to the treatment efficacy study dataset outlined in Chapter 1. Mul-
tiple survival (time-to-event) processes were generated in this study. These pro-
cesses were the time to gametocyte emergence, the time to gametocyte clearance
and the time to early exit from the study due to either treatment failure or loss-
to-follow-up. The selection of covariates discussed in Chapter 1 was used to fit
various parametric and Cox regression models to the data.
A basic model building approach was applied in this study. This approach
involved firstly fitting models with different underlying distribution assumptions
and the same set of covariates, to the data. These fitted models were then
compared using AIC statistics as well as Cox-snell residual plots. The selected
model was then refined by excluding non-significant covariates. The resulting
AIC and deviance test statistics were used to assess the impact of each covariate
removal. In addition Cox-Snell residual plots were generated for each of the
fitted models to assess model fit, with the results helping to guide the decision
into the final model to apply to the data.
Focus is only on the modeling of the location parameter, when analyzing
parametric survival models in this investigation, with no modeling applied to any
of the ancillary parameters. This approach is applied for ease of interpretation
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of results across models.
This section will proceed as follows, firstly the time until gametocyte emer-
gence will be investigated. This investigation will lead to a better understanding
of the risk factors that influence the emergence of gametocytes. Subsequently,
an analysis into the duration of gametocytemia will be conducted. Finally an
investigation will be conducted into the factors that influence the exit of patients
from the study, with the aim of trying to understand the censoring mechanism
affecting the observation of the gametocyte profile.
3.5.1 Time to gametocyte emergence
The factors that affect the emergence of gametocytes are of particular interest
in combating the transmission of malaria. In this section, the main interest is
in evaluating the factors that influence whether or not gametocytes emerge and
not necessarily those for predicting the time until gametocytes emerge. As a
result proportional hazard models were used in this analysis. These include the
Cox, exponential and Weibull proportional hazard models.
The first step in this analysis involved testing the validity of the proportional
hazards assumption. Figure 10 provides a graphical test of the proportional
hazards assumption. This figure illustrates the relationship between the log cu-
mulative hazard function and time, across the different strata of the categorical
variables used in this analysis. This plot reveals that the difference between the
log cumulative hazard plots of the two treatments, is smaller at observation day
3 as compared to observation day 7. However from observation day 7 onwards
the log cumulative hazard plots of the two treatments are fairly parallel. It
can also be seen that the difference between the log cumulative hazard plots
for the presence and absence of moderate anaemia is greater at observation day
3 as compared to observation day 7, with the difference remaining fairly con-
stant from observation day 7 onwards. The covariates for parasite resistance
(mut5) and patient gender also exhibit minor deviations from the proportional
hazards assumption. However, none of the deviations from the categorical co-
variates shown in Figure 10 appear to be significant enough to make the overall
proportional hazards assumption invalid.
Proportional hazard models were fit to the data and the estimated β coeffi-
cients, derived under the proportional hazards framework, with their associated
confidence intervals are shown in Table 12. It can be seen that the Weibull
model had the lowest AIC statistic. However, an evaluation of the Cox-snell
residuals, shown in Figure 11, revealed that the Cox model provided a better
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Figure 10: Plots of logH(t) against time for the time to gametocyte emergence
process, stratified by categorical predictor variables
plots, it was decided that the Cox model was the most appropriate model to
consider for further investigation.
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The fitted Cox model was refined by systematically removing non-significant
covariates from the model and subsequently assessing the impact of this action
on the AIC statistic. Since the models being compared are nested, the deviance
test was also applied in the model building process. The results of this process
are shown in Table 13. It can be seen that removing non-significant covariates
had a small impact on the AIC statistics across all the models. In addition there
is a small change in the parameter estimates and confidence intervals, for the
covariates remaining after variable deletion. The deviance test revealed that
there was a moderately significant difference between models C2 and C3. A
comparison of the Cox-Snell residuals plots, for the fitted models, is provided in
Figure 12. This figure reveals that model C2 provides a better fit to the data as
compared to model C3. Based on the model fitting results, it was decided that






























































































































































































































































































































































































































































































































Figure 12: Cox-Snell residual plots for the Cox PH models
Deviance residual plots were created for model C2 in order to assess its
overall model fit. These plots are shown in Figure 13. These residual plots
indicate that the deviance residuals have a symmetric distribution. In addition
there do not appear to be any significantly large outliers, with the range of the
residuals being -1.80 to 2.81. The residuals have a mean -0.07 and a standard
deviation of 1.08 that is in line with expectations as these residuals are assumed
to follow a standard normal distribution with a mean of 0 and a standard
deviation of 1. Looking at each of the categorical covariates separately, it can be
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seen that the medians of the deviance residuals are generally less than 0 implying
that the observed times to emergence are smaller than expected. However, this
































































































































































































































































































































































































































































































































































































































































































































































































































































Deviance residuals vs ratio


































































































































































































































































































































































































Deviance residuals vs pzero











Figure 13: Deviance residual plots for the, Model C2, time to gametocyte emer-
gence Cox PH survival model
The model fitting results from Model C2 revealed that treatment, parasite
reduction ratio at 24 hours, the prevalence of moderate anaemia and baseline
asexual parasite density all had strong associations with the hazard of gameto-
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cyte emergence. Additionally the prevalence of quintuple mutations and gender
were found to have a moderate association with the hazard of gametocyte emer-
gence as their confidence intervals can be seen to be predominately positive.





This model can be interpreted as follows
• Receiving a combination of artesunate and sulfadoxine-pyrimethamine
treatment as compared to sulfadoxine-pyrimethamine treatment only, re-
duces the hazard of gametocyte emergence by 59.6% (= 1− e−0.908).
• Clearing all baseline asexual parasites in the first 24 hours leads a 52.2%
(= 1− e−0.738) reduction in the hazard of gametocyte emergence.
• Patients with moderate anaemia have a 38.2% (= e0.323−1) higher hazard
of gametocyte emergence as compared to patients with a haemoglobin
density > 11g/dL.
• Patients with 5 mutations have a 33.1% (= e0.286 − 1) higher hazard
of gametocyte emergence as compared to patients who have less than 5
mutations.
• Every ten-fold increase in the baseline asexual parasite density results in
a 7.0% (= e0.068 − 1) increase in the hazard of gametocyte emergence.
• Being a male patient increases the hazard of gametocyte emergence by
27.6% (= e0.244 − 1) as compared to being a female.
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3.5.2 Time to gametocyte clearance
Time to gametocyte clearance and hence the duration of gametocytemia, was
treated as the time-to-event process in this section. The aim of this section
was to estimate the duration of gametocytemia, thus only AFT models were
considered for this analysis since they can be explicitly used to estimate time.
The exponential, generalized-gamma, log-logistic, log-normal and Weibull AFT
models were used in this section. The flexsurv (Jackson, 2016) package, in R
(R Core Team, 2015), was used to fit the aforementioned AFT models. This
package was selected because it can accommodate the 3 parameter generalized-
gamma AFT model.
In order to model the duration of gametocytemia, only patients who expe-
rienced gametocytemia were considered in the analysis. As a result the risk
factors identified in this analysis would only be applicable to this cohort of
patients. From the 609 patients included in the study, only 239 patients experi-
enced gametocytemia. 195 of these patients cleared their gametocyte infection
during the course of the study. As previously stated, it will be assumed that
gametocyte clearance occurs at the midpoint of an observation interval. That
is if a patient was observed to have gametocytes in their blood on day 7 but
not on day 14, it would be assumed that gametocyte clearance occurred on day
10.5.
In this analysis an additional adjustment was required for patients who were
observed only once in the study. It was assumed that these patients were ob-
served for a period of 1 day before they were censored. This assumption affected
18 patients included in the analysis. This adjustment is not expected to have a
significant impact on the model fitting results.
Table 14 shows the results of the AFT models fit to the data. It can be seen
that the generalized-gamma, log-normal and Weibull models had the lowest
AIC statistics, with there being a small difference between these models. It
was previously stated that several of the AFT models used in this section were
simplifications of the generalized-gamma model. Table 9 showed the constraints
required to simplify the generalized-gamma distribution into the exponential,
log-normal and Weibull distributions. These constraints were
• Exponential {q = 1 and σ = 1}
• Log-Normal {q = 0}
• Weibull {q = 1}.
Based on the results of the generalized-gamma AFT model fit, it can be con-
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cluded that the null hypothesis of q = 0 cannot be rejected; as the 95% con-
fidence interval for the parameter overlaps with 0. This would imply that the
log-normal model would be an adequate model to apply to the data. However,
an evaluation of the Cox-Snell residuals for these fitted models (Figure 14) indi-
cates that both the generalized-gamma and the log-normal models do not fit the
data well. This is because the Cox-Snell residual plots for these models deviate
from the straight line that runs through the origin with a gradient of 1. It can
be seen, from Figure 14, that the Weibull model provides an adequate fit to
the data. Based on the preceding information it was decided that the Weibull
model would be considered for further investigation.
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The Weibull model shown in Table 14 was refined by systematically exclud-
ing non-significant variables and assessing the impact on the AIC statistic of the
resulting model. Deviance tests and Cox-snell residual plots were used in con-
junction with the AIC statistic, to determine the final model. Table 15 shows
the results of the model fits from the model building process along with the
resulting AIC statistics. It can be seen that there is a small change in the AIC
statistics across all the models. It is also evident that parameter estimates do
not change dramatically as non-significant variables are systematically excluded
from the models being fit. Deviance test reveals that there is no significant dif-
ference between any of the fitted models. These findings lend support to model
W6 as it is a simplified model that is not significantly different from the other
more complex models that were fit to the data. However, Cox-snell residual
plots (Figure 15) reveal that W4 was the simplest model that had an adequate
Cox-snell residual plot. Taking all the preceding information into account, it










































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 15: Cox-Snell residual plots for the Weibull time to gametocyte clearance
models
Deviance residual plots were created for model W4 in order to assess its over-
all model fit. These plots are shown in Figure 16. The range of these residuals
is -2.15 to 2.52, which implies that there are no significantly large outliers. The
residuals have a mean of -0.23 and a standard deviation of 1.09, which is in line
with the distributional assumptions of deviance residuals that assume normality
with a mean of 0 and standard deviation of 1. It is acknowledged that the neg-
































































































































































































































































































































































































































































Deviance residuals vs ratio




































































































































































































Deviance residuals vs pzero











Figure 16: Deviance residual plots for the, Model W4, time to gametocyte
clearance Weibull AFT survival model
the time to clearance. However, this overestimation is small thus, model W4 is
an appropriate model to apply to this cohort of lives.
Model W4, for the ith patient, is defined as
log(Ti) = α0 + (trti × α1) + (ratioi × α2) + (pzeroi × α6) + (genderi × α7),
and it can be interpreted as follows
• Receiving a combination of artesunate and sulfadoxine-pyrimethamine
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treatment as compared to sulfadoxine-pyrimethamine treatment only, de-
creases the time to gametocyte clearance by 64.5% (= 1− e−1.036).
• Clearing all baseline asexual parasites in the first 24 hours decreases the
time to gametocyte clearance by 17.9% (= 1− e−0.197).
• The time to gametocyte clearance increases by 10.4% (= e0.099) with every
ten-fold increase in the baseline asexual parasite density.
• Being a male patient increases the time to gametocyte clearance by 9.2%
(= e0.088) as compared to being a female patient.
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3.5.3 Estimation of the duration of gametocytemia
The time to gametocyte clearance AFT models, outlined above, were derived
using a sample of the population that experienced gametocytemia. It can be
argued that this group of patients is the least healthy segment of the population.
As a result the estimated durations from this group cannot be used to make pre-
dictions on the overall population, as these predictions would be biased toward
longer durations. A possible solution to this problem would involve incorpo-
rating the prevalence of gametocytemia into the estimation of the duration of
gametocytemia. This methodology is outlined below.
Given that a Weibull AFT model has been fit to the dataset of individuals
who exhibited gametocytemia, the duration of gametocytemia for the ith patient
(si) is determined as the area under the graph of the Weibull survival curve.










The estimated durations from Equation 36 would be expected to overestimate
the duration of gametocytemia for the full population. In order to adjust the
estimated durations to a population level, the prevalence of gametocytemia
must be considered. The prevalence of gametocytemia is incorporated into the
estimation of duration as follows
di = si × πi, (37)
where di is the adjusted duration and πi is the estimated probability of that
individual developing gametocytes, which is based on the patient’s covariate
pattern. The prevalence of gametocytemia (πi) is modeled using logistic re-
gression. Since the Weibull AFT model is derived on the log-scale, it is more
appropriate to model the prevalence of gametocyte on the same scale as it allows
for a simpler derivation of the variance structure for the adjusted duration esti-
mate. Taking this approach leads to the use of the log-link function, as opposed
to the logit link function, in the modeling of gametocyte prevalence. This is
shown in Equation 38 below.
log(πi) = x
T
i βB , (38)
where xi is a set of p observed covariates x
T
i = (xi1, . . . , xip), for the i
th patient
and βB is a p dimensional vector of fixed effect coefficients. Assuming that the
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prevalence of gametocytemia is independent of the duration of gametocytemia,
the following relationship can be defined on the log-scale
log di = log(si × πi)
= log si + log πi.
(39)
Applying a simplifying assumption that si and πi are independent leads to a
variance structure of
Var(log di) = Var(log si) + Var(log πi). (40)
Equation 40 can thus be used to derive the confidence interval for the adjusted
duration on the log-scale. Confidence intervals for di can subsequently be de-
rived by using the delta method (Oehlert, 1992). The delta method allows for
the approximation of the mean and variance of a function that is a transfor-
mation other random variables. The method applies a first-order Taylor series
expansion about the mean of a function to derive an approximation for its vari-
ance. The Taylor series expansion for a differentiable function G(X), where X
is an asymptotically normally distributed random variable with a mean of µ, is
given as
G(X) = G(µ) + {(X − µ)×G
′
(µ)}.
It follows that the variance of G(X), using the Taylor series approximation, is
given by






In this analysis X is log di, G(.) is the exponential function and µ is the linear
predictor of the fitted Weibull AFT model on the log-scale. This implies that
Var[d̂i] = Var(log d̂i)× [d̂i]2.
Since the adjusted duration is based on patient covariate patterns and not
the actual observed patients, it is possible to derive the prevalence model based
of the full dataset of 609 patients. The parameter estimates from this model
would then be combined with the parameter estimates from the Weibull time to
clearance model in order to estimate the adjusted duration for a generic patient
who has a specific covariate pattern.
A similar model building process to that used throughout this chapter was
applied in the derivation of the appropriate prevalence model. The results of
the model building process are shown in Table 16. It can be seen that there
is a small change in the AIC statistics across all models. Model B4 appeared
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to be the most appropriate model as it was the model that consisted of only
covariates that had a strong association with the prevalence of gametocytemia.
In addition the deviance tests that were applied revealed that this model was
not significantly different from the more complicated models that were fit in
this analysis.
The model fitting results from Model B4 revealed that treatment, the first
24 hour parasite reduction ratio, baseline asexual parasite density and patient
gender had strong associations with the prevalence of gametocytemia, as their
95% CIs did not include 0. Model B4 is defined as
log(πi) = βB0 +(trti×βB1)+(ratioi×βB2)+(pzeroi×βB6)+(genderi×βB7),
and it can be interpreted as follows
• Receiving a combination of artesunate and sulfadoxine-pyrimethamine
treatment as compared to sulfadoxine-pyrimethamine treatment only, re-
duces the relative risk of gametocytemia by 52.5% (= 1− e−0.744).
• Clearing all baseline asexual parasites in the first 24 hours reduces the
relative risk of gametocytemia by 38.0% (= 1− e−0.479).
• Every ten-fold increase in the baseline asexual parasite density increases
the relative risk of gametocytemia by 6.2% (= e0.060 − 1).
• Male patients have a 20.3% (= e0.185 − 1) higher relative risk of gameto-













































































































































































































































































































































































































































































































































































































Equation 37 outlined the methodology required to estimate the population
level duration of gametocytemia. This method involved using a patient’s specific
covariate pattern to combine the estimated prevalence of gametocytemia with
the estimated duration gametocytemia. The confidence intervals associated
with these duration estimates would subsequently be estimated using the delta
method. These predicted durations are shown in Table 17 and they allow for
the comparison of the following characteristics
• Sulfadoxine-pyrimethamine treatment only (SP) and a combination treat-
ment of artesunate and sulfadoxine-pyrimethamine (ACT).
• “High” log10 baseline asexual parasite density of 17.754 relative to a “Low”
baseline asexual parasite density of 5.
• “High” first 24 hour parasite reduction rate of 100% relative to a “Low”
first 24 hour parasite reduction rate of -31.4%.
• Female patients compared to male patients.
The 2.5 and the 97.5 percentiles for the baseline asexual parasite density and
the first 24 hour parasite reduction ratio were used as the respective low and
high covariate values described above.
The following steps were taken to derive the predicted adjusted durations
1. A dataset with the levels given above (used for comparison) was created.
2. The parameter estimates from Model W4 were used to estimate the du-
ration of gametocytemia on the log-scale.
3. The parameter estimates from Model B4 were used to estimate the preva-
lence of gametocytemia on the log-scale.
4. The estimates of duration and prevalence, on the log-scale given above,
were combined as per Equation 39 in order to generate estimates for the
adjusted duration on the log-scale.
5. The adjusted duration on the original scale was derived by taking the
exponent of the log-scale adjusted durations. Subsequently the confidence
intervals of the adjusted durations, on the original scale, were calculated
using the delta method.
Table 17 reveals that the covariate patterns with the longest adjusted duration
have the following characteristics
• Male patients
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• Receive sulfadoxine-pyrimethamine treatment only
• Have a high baseline asexual parasite density
• Have a low first 24 hour parasite reduction ratio
Table 17: Estimated prevalence and duration of gametocytemia (95% CI), in
days.




F 0.34 (0.22 ; 0.46) 7.23 (4.91 ; 10.65) 2.45 (1.17 ; 5.40)
M 0.41 (0.26 ; 0.55) 7.9 (5.30 ; 11.77) 3.22 (1.49 ; 7.21)
High
F 0.18 (0.11 ; 0.25) 5.58 (3.59 ; 8.69) 1.01 (0.40 ; 2.44)
M 0.22 (0.13 ; 0.31) 6.10 (3.92 ; 9.49) 1.32 (0.52 ; 3.24)
High
low
F 0.73 (0.57 ; 0.88) 25.57 (20.23 ; 32.32) 18.64 (12.73 ; 31.48)
M 0.88 (0.71 ; 1.05) 27.93 (22.04 ; 35.39) 24.49 (17.01 ; 40.71)
High
F 0.39 (0.28 ; 0.50) 19.74 (14.81 ; 26.31) 7.67 (4.54 ; 14.68)




F 0.16 (0.08 ; 0.24) 2.57 (1.68 ; 3.92) 0.41 (0.15 ; 1.06)
M 0.19 (0.10 ; 0.29) 2.80 (1.82 ; 4.32) 0.54 (0.19 ; 1.40)
High
F 0.09 (0.05 ; 0.12) 1.98 (1.39 ; 2.82) 0.17 (0.08 ; 0.39)
M 0.10 (0.06 ; 0.15) 2.16 (1.52 ; 3.08) 0.22 (0.10 ; 0.52)
High
low
F 0.35 (0.19 ; 0.51) 9.07 (5.43 ; 15.15) 3.14 (0.98 ; 8.42)
M 0.42 (0.23 ; 0.60) 9.91 (5.93 ; 16.55) 4.13 (1.32 ; 10.98)
High
F 0.18 (0.11 ; 0.26) 7.01 (4.54 ; 10.82) 1.29 (0.54 ; 3.07)
M 0.22 (0.14 ; 0.31) 7.65 (5.00 ; 11.71) 1.70 (0.73 ; 3.98)
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3.5.4 Time to early exit from the study
In the previous section the time to gametocyte clearance was investigated. This
was done in the presence of censoring, which arose in the form of treatment
failure and loss-to-follow-up. These two forms of censoring are examples of
informative censoring. Informative censoring arises when the experience of pa-
tients who exit the study is different to the experience of patients who remain
in the study.
It can be hypothesized that the patients who experience treatment failure
have high densities of asexual parasites in their system for an extended period of
time. These high densities of asexual parasites would be expected to develop into
gametocytes, which would result in these patients having a higher prevalence of
gametocytemia as compared to patients who stay in the study. It can possibly be
assumed that patients who have successfully overcome their malaria infection are
more likely to exit the study before it is completed, resulting in loss-to-follow-up.
The implication of this assumption is that the prevalence of gametocytemia in
patients who are lost-to-follow-up is less than the prevalence of gametocytemia
in the patients who remain in the study. Alternatively, loss-to-follow-up my
be due to reasons that are unrelated to the study like relocation for work or
accidental death. The implication of loss-to-follow-up being not at random is
that it becomes a competing cause of early exit from the study, to the treatment
failure cause of exit.
This section will begin by investigating the risk factors for the hazard of early
exit from the study, due to either treatment failure or loss-to-follow-up, using
proportional hazard models. This involves combining treatment failure and loss-
to-follow-up in order to create a single event classified as early exit from the
study. The next step will involve extending the analysis into a cause-specific
investigation, whereby treatment failure and loss-to-follow-up are treated as
competing events.
Before beginning the time to early exit analysis, a test of the proportional
hazards assumption was conducted. This test was performed graphically by
assessing the relationship between the log cumulative hazard function and time,
across different strata of the categorical variables used in this analysis. The re-
sults of this test are presented in Figure 17. It can be seen that the proportional
hazards assumption for patient gender is not appropriate as the log cumulative
hazard plots for males and females cross over after day 7. The log cumula-
tive hazard functions for the different strata, of each of the other categorical
variables, remain fairly parallel over time thus implying that the proportional
hazards assumption if appropriate for them. Overall it appeared as though the
67
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Figure 17: Plots of logH(t) against time for the time to early exit process,
stratified by categorical risk factors.
The Cox, exponential and Weibull proportional hazard models were fit to
the data and the estimated β coefficients, along with their confidence intervals,
are shown in Table 18. It can be seen that the Weibull model has the lowest AIC
statistic, with the exponential model having a moderately higher AIC statistic.
It is also evident that there is a close similarity in the estimated coefficients
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between the exponential and Weibull models. A comparison of the Cox-Snell
residual plots for the fitted models is provided in Figure 18. This plot suggests
that the exponential and Weibull models fit the data adequately. The exponen-
tial model is a special case of the Weibull model, where ρ = 1. It can be seen
that the confidence interval for ρ, under the Weibull model, does not include 1.
As a result is can be concluded that the ρ parameter is significantly different
from 1, which implies that the Weibull model is the most appropriate model to
consider for further investigation.































































































































































































































































































































































































































































































































































Similarly to the previously defined model building processes outlined in
this chapter, non-significant covariates were systematically removed from the
Weibull model provided in Table 18. The impact on the change in the AIC
statistic and the resultant deviance test, was used as the criteria in deciding
the most appropriate fitted model. The results of the model building process
are shown in Table 19. The results show that there is a small change in the
AIC statistics, as non-significant covariates were being removed from the fitted
models. In addition it can be seen that there is a small change in the parameter
effect sizes of the covariates remaining in the fitted models, after the removal
of non-significant covariates. The Cox-snell residuals, shown in Figure 19, were
created to assess the adequacy of the individual models fit to the data. These
plots revealed that all the fitted models were broadly appropriate.
Based on all the preceding information, it was decided that Model W5 was
the most appropriate model to consider for further investigation. This was
because all its covariates had a significant effect on the hazard of early exit
from the study. In addition the results of the deviance tests, which compared
Model W4 to Model W5, indicated that the presence of an additional non-
significant covariate did not significantly improve the fit of Model W4 to the
data as compared to Model W5.
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Deviance residual plots were created for Model W5 in order to assess its
overall model fit. These plots are shown in Figure 20. There do not appear to
be any significantly large outliers, with the range of the residuals being from
-2.92 to 1.62. The residuals have a mean 0.16 and a standard deviation of 0.98,
which is in line with expectations. However, it can be seen that the deviance
residuals have a high proportion of small positive residuals that are offset by
fewer relatively larger negative residuals. The implication is that the observed
times to exit are larger than expected. These discrepancies were considered to
be minor and not enough to disprove the conclusion that model W5 was an
appropriate model.
The covariates in Model W5 all had strong associations with the hazard of
early exit from the study, as their 95% CIs did not include 0. These covari-
ates were the first 24 hour parasite reduction ratio, the prevalence of quintuple
mutation and patient age. Model W5 is defined as
hi(t) = λρt
ρ−1 exp[(ratioi × β2) + (mut5i × β4) + (lagei × β5)],
and it can be interpreted as follows,
• Clearing all baseline asexual parasites in the first 24 hours leads to a 55%
(= 1− e−0.800) reduction in the hazard of early exit from the study.
• Patients with quintuple mutations present have a 2.91 (= e1.068) fold
higher hazard of early exit as compared to patients with less than 5 mu-
tations.
• Doubling patient age leads to a 14.2% (= 1 − e−0.154) reduction in the

















































































































































































































































































































































































































































































































































































































































Deviance residuals vs ratio























































































































































































































































































Figure 20: Deviance residual plots for the, Model W5, time to early exit from
the study Weibull PH survival model
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3.5.5 Cause-specific hazard analysis
As previously stated, the underlying characteristics of patients who exit the
study can be very different depending on whether they were lost-to-follow-up
or whether they experienced treatment failure. If the hypothesis that the cause
of exit from the study is related to a patient’s health status is correct, it would
be expected that the risk factors used in this analysis would behave differently
depending on the cause of exit being investigated. A cause-specific hazards
analysis allows for the impacts of the risk factors, considered in this study, to
be investigated with reference to each cause of early exit.
A cause-specific hazard model was fit to the data under the proportional haz-
ards framework. Tests for the validity of the proportional hazards assumption
are shown in Figure 21 and Figure 22 for the treatment failure and loss-to-
follow-up causes of exit respectively. Considering the plots for the treatment
failure cause of exit, it can be seen that the plots for patient gender cross over
after 7 days, in addition the plots for the treatment effect cross over after day
3. When considering the plots for the LTFU cause of exit, the prevalence of
mutation plots cross over at a couple of observation days, in addition treatment
effect and gender plots can also be seen to cross over a certain points. These
plots do raise some concerns around the validity of the proportional hazards
assumption. However, since the plots are predominately parallel across the co-
variates considered, it was assumed that the proportional hazards assumption
was valid.
A comparison of the cause-specific proportional hazard models is provided in
Table 20. This table provides a comparison of the Cox, exponential and Weibull
proportional hazard models. It can be seen that the parameter estimates, by
cause of exit, were broadly the same across all the fitted models. The Cox
proportional hazards model provides the lowest overall AIC statistic. However,
Figure 23 reveals that the Weibull model provides a moderately better fit to
both the treatment failure and loss-to-follow-up causes of exit. The Weibull
model was thus selected as the final model to apply to the data. For ease
of comparison between the two causes of exit no further model refinement, in
respect of covariate selection, was applied.
The Weibull model is a combination of the treatment failure and the loss-
to-follow-up (LTFU) hazard functions. The hazard functions are defined as
hFi(t) = λF ρF t
ρF−1 exp[(trti × βF1) + (ratioi × βF2) + (anaemiai × βF3) + (mut5i × βF4)
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ρL−1 exp[(trti × βL1) + (ratioi × βL2) + (anaemiai × βL3) + (mut5i × βL4)
+ (lagei × βL5) + (pzeroi × βL6) + (genderi × βL7)],
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Figure 23: Cox-Snell residual plots for the cause specific time to early exit
models
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The interpretation of the Weibull cause-specific model is provided in Table
21. It can be seen from Table 20 that the treatment effect is highly significant
once the two causes of early exit are isolated. The rationale behind artemisinin-
based combination therapy is that adding an artemisinin derivative such as
artesunate to sulfadoxine-pyrimethamine results in more rapid clearance of both
asexual parasites and fever, a reduction in gametocyte carriage and a reduction
in the risk of treatment failure. As artesunate and sulfadoxine-pyrimethamine
have different mechanisms of action, the probabilities of a parasite being re-
sistant to both antimalarials is markedly reduced. The interpretation of the
effect of treatment, under the Weibull cause-specific hazards survival model,
thus makes clinical sense. This is because the hazard of treatment failure for
patients receiving ACT treatment would be expected to be significantly less than
that of patients receiving SP treatment only. In addition since the signs and
symptoms of malaria are expected to be relieved timeously in patients receiving
ACT treatment, there would be less incentive for these patients to remain in
the study once their health has improved. These findings add weight to the
argument that both causes of early exit from the study are forms of informative
censoring. It is important to note that treatment was the only covariate that
had a strong association with the hazard of LTFU.
With regards to the hazard of treatment failure; patient gender and the
prevalence of moderate anaemia did not have an association with the hazard of
treatment failure. Baseline parasite density had a moderate association as its
95% CI was predominately positive, with the remaining covariates all having
strong associations with the hazard of treatment failure.
Figure 24 provides a graphical illustration of the predicted hazard func-
tions arising from the cause-specific hazards analysis, by treatment. These plots
stack the predicted hazard functions arising from the LTFU and treatment fail-
ure, causes of early exit. As a result the highest curve on each of the plots is
representative of the overall hazard of early exit arising from either LTFU or
treatment failure. The predicted hazard rates were made on a male patient,
with a haemoglobin density > 11g/dL, 5 mutations present, median log10 base-
line asexual parasite density (13.7), median first 24 hour parasite clearance rate
(28.3%) and median patient age of 12 years (lage = 3.6). It can be seen that the
hazard of treatment failure is greater in patients receiving SP treatment only,
as compared to ACT treatment. In addition it can be seen that the hazard
of LTFU was greater in patients receiving ACT treatment as compared to SP
treatment only.
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Table 21: Interpretation of the Weibull Cause-specific PH model.
Definition Treatment Failure Loss-to-follow-up (LTFU)
trt Receiving ACT treatment, as compared to
SP treatment, reduces the hazard of treat-
ment failure by 72%
Receiving ACT treatment, as compared to
SP treatment, leads to a 2.7 fold increase
in the hazard of LTFU
ratio Clearing all baseline asexual parasites in
the first 24 hour is associated with a 58%
reduction in the hazard of treatment failure
The first 24 hour parasite reduction ratio
does not have an association with the haz-
ard of LTFU
anaemia Anaemia status does not have an associa-
tion with the hazard of treatment failure
Anaemia status does not have an associa-
tion with the hazard of LTFU
mut5 Having 5 mutations leads to a 4 fold in-
crease in the hazard of treatment failure
The prevalence of quintuple mutations
does not have an association with the haz-
ard of LTFU
lage Doubling patient age reduces the hazard of
treatment failure by 16%
Patient age does not have an association
with the hazard of LTFU
pzero Every ten-fold increase in the baseline
asexual parasite density results in a 7% in-
crease in the hazard of treatment failure
Baseline asexual parasite density does not
have an association with the hazard of
LTFU
gender Patient gender does not have an associa-
tion with the hazard of treatment failure
Patient gender does not have an associa-
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LTFU
Failure
Figure 24: Stacked cause-specific hazard plots for LTFU and treatment failure
causes of exit, by treatment
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4 Joint Models
4.1 Overview of joint modeling techniques
Time-to-event and longitudinal (repeated measures) data were generated in this
analysis. The modeling of the longitudinal gametocyte profile is a key area of
focus in this thesis. It has been shown, in Chapter 2, that gametocyte profiles
are zero-inflated and that they have a nonlinear relationship with time. Another
feature of these profiles is that some patients have incomplete profiles, as they
do not have gametocyte measurements at all observation times. Examples of
individual gametocyte profiles are shown in Figure 25.
It was discussed in Chapter 3, that an informative censoring mechanism may
be prevalent in this study. As a result standard longitudinal models fit to the ob-
served data would be expected to give biased parameter estimates. Faucett and
Thomas (1996) highlighted how non-random dropout led to biased estimates in
their analysis of CD4 count progression over time. Another feature of longitu-
dinal data is measurement error. Measurement error can arise, in longitudinal
studies, due to erroneous measurement readings or due to short-term biological
variability in patients (Wang and Taylor, 2001). Prentice (1982) showed that
failure to account for measurement error, in longitudinal measurements included
in a survival analysis model as time-dependent covariates, would lead to biased
hazard estimates and incorrect variance estimates. Joint models can be used to
correct for the bias in parameter estimation, which arises when modeling both
the survival and longitudinal processes. The relationship between missing data
and joint models will be expanded upon in the next section.
An overview of the joint modeling framework, that was applied in this anal-
ysis, is presented in this chapter. This overview considers generic longitudinal
and survival processes in its development. The survival and longitudinal sub-
models were then subsequently investigated further and made more specific to
this analysis. The methodology applied was an extension of the work by Hen-
derson et al. (2000), which involved the use of latent random effects in the joint
model formulation. The complex likelihood functions developed in this chapter
were estimated under the Bayesian framework. The resulting joint posterior dis-
tributions of the parameters, to be estimated, were analytically intractable thus
Markov Chain Monte Carlo (MCMC) methods were used to obtain the point
and interval estimates of parameters (Ghosh et al., 2006). The survival process
included in the joint model is usually reflective of the informative censoring
mechanism taking place in the data. In this analysis the informative censoring
mechanism was characterized by the time to early exit survival process. As a
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result this process was included in the joint models that were applied in this
chapter.
Two types of longitudinal submodels were considered in this analysis. These
models can be characterized as those that ignore the zero-inflation in the data
and those that account for it. Models that ignore zero-inflation are referred
to as Nonlinear (NL) joint models while the models that accounted for the
zero-inflation are referred to as zero-adjusted gamma (ZAG) joint models.
This chapter will proceed as follows, firstly notation that will be applied in
this chapter will be presented. Secondly, the relationship between missing data
and joint models will be discussed. Subsequently the joint models that were
applied to the data generated by this study will be described. Finally these
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Figure 25: Observed Gametocyte profiles (black circles) for selected patients.
The first row shows profiles for successful treatment outcomes, the second row
shows profiles of patients lost-to-follow-up and the third row shows profiles of
patients who experienced treatment failure
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4.2 Notation
Given that there are m patients who are followed up for a period [0, c], where
in the case of this analysis c ≤ 42, the number of observations collected for the
ith patient is ni (∀i = 1, . . . ,m) with the total number of observations collected
during the study given as n =
∑m
i=1 ni. These observations are collected, for the
ith patient, at visitation times sij (∀j = 1, . . . , ni). The observed gametocyte
density recorded for the ith patient at the jth visit is given as yij . The observed
covariates are defined as xij , where xij is a p-dimensional vector, with the same
covariates being applied to both the survival and longitudinal submodels. In
this analysis only baseline covariates were considered thus xij simplifies to xi.
The corresponding p dimensional vector of fixed effect coefficients, for the ith
patient, is defined as θi. The covariates for the random effects are defined as zi
with associated random effect parameters of bi.
The time that the last gametocyte reading was taken is given as ti and the
reasons for that timepoint being the last observed time can either be a result of
treatment failure, loss-to-follow-up or the end of the study. In addition consider
that the response vector for a ith patient, who is censored during the study,
consists of an observed (yoi ) and a missing component (y
m
i ). The observed
component consists of all observations collected up to the event time, whilst
the missing component contains observations that would have been collected
up to the end of the study if the patient had remained in the study. Interval
censoring also gives rise to missing data, as the ymi observations can fall in
between observed timepoints. The response vector for the ith subject is thus




i ). A missing data indicator will also be introduced as
rij =
 1 if yij is observed0 otherwise .
The missing data indicator vector is thus ri and the associated underly-
ing missingness mechanism is defined as wi with ϑ as the set of missingness
parameters.
4.3 Missing data mechanisms
In malaria intervention studies, gametocyte longitudinal profiles are generally
incomplete. Early exit from the study, either due to loss-to-follow-up or treat-
ment failure, is responsible for the incomplete profiles. Missing data arising from
early exit from the study are referred to as monotone missingness. Intermittent
missingness is an additional form of missingness, which arises in these studies,
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whereby a patient misses some follow-up visits but returns to the study before
it ends.
A key problem with missing data is a loss of efficiency, as additional patients
need to be recruited into the study to achieve a specific level of power required to
detect significant effects. An additional problem is bias in parameter estimates,
in the event of informative censoring.
There are several approaches that can be used to handle missing data. A
common approach used in most statistical packages is the deletion of information
from patients who had missing values. An analysis that uses this approach is
referred to as a “complete-case analysis” or “per protocol analysis”. Estimates
that are derived from this approach can be biased if the individuals excluded
from the study are significantly different from those who remain. Additional
approaches involve the imputation of the missing data. A simple imputation
approach is referred to as the “last observation carried forward” approach. In
this approach the missing responses are replaced by the last observed responses
from the patient. A problem with this approach is that it underestimates the
variability of the patient’s responses, as it assumes that the missing responses
are constant. Inverse probability weighting can also be used to deal with missing
data. In this approach observed data is weighted by the inverse of the probability
that the data was observed (Seaman and White, 2013). Little and Rubin (2002)
proposed a more sophisticated multiple imputation approach. This approach
involves the use of a statistical model to impute M values for each of the missing
datapoints, thereafter M statistical analyses are conducted on the reconstituted
datasets (i.e. datasets where the missing observations have been replaced). This
is an example of explicit imputation.
The aim of the analysis conducted in this chapter is the imputation of incom-
plete gametocyte profiles. The method to be used depends on the underlying
missingness mechanism. Authors like Fitzmaurice et al. (2004) and Molen-
berghs and Kenward (2007) outlined three types of missingness mechanisms.
These mechanisms are Missing Completely at Random (MCAR), Missing at
Random (MAR) and Missing not at Random (MNAR).
A MCAR mechanism refers to the scenario where the outcomes are com-
pletely unrelated to the missingness process, as a result the full data density is
given as
f(yi, ri|xi, zi,wi,θ,ϑ) = f(yi|xi, zi,θ)f(ri|wi,ϑ). (41)
It is thus implied that the observed responses are independent of the missingness
process, which means that the missingness mechanism does not need to be
considered in the analysis of the observed responses. This allows Equation 41
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to be simplified to
f(yoi , ri|xi, zi,wi,θ,ϑ) = f(yoi |xi, zi,θ)f(ri|wi,ϑ).
A MAR mechanism refers to the scenario where the probability of miss-
ingness is conditionally independent of the unobserved data (ymi ), given the
observed data (yoi ). This implies that
f(ri|yoi ,ymi ,wi,ϑ) = f(ri|yoi ,wi,ϑ),
which leads to a density of
f(yoi , ri|xi, zi,wi,θ,ϑ) = f(yoi |xi, zi,θ)f(ri|yoi ,wi,ϑ). (42)
The missingness process in the scenario above can be referred to as “ignorable”,
since the θ and ϑ are not related. As a result, likelihood based analysis con-
ducted using only the observed data would give an appropriate result, provided
that the model for the measurement process is correctly specified.
The MNAR mechanism is associated with informative censoring. Under this
mechanism, the probability of a missing response is dependent on the unobserved
data. As a result there is a convolved relationship between the observed data
and the missingness process, which can be give rise to the following density
f(yoi , ri|xi, zi,wi,θ,ϑ) =
∫
f(yi|xi, zi,θ)f(ri|yi,wi,ϑ)dymi . (43)
It is evident that the missingness process cannot be ignored and valid inferences
can only be obtained when an analysis is conducted using a joint distribution
of the measurement and missingness processes. Authors like Molenberghs and
Kenward (2007), Little (1995) and Daniels and Hogan (2008) outlined three
model families that can be used for the aforementioned joint distribution. These
families are selection models, pattern mixture models and shared-parameter
models.
The selection model defines a full dataset density of
f(yi, ri|xi, zi,wi,θ,ϑ) = f(yi|xi, zi,θ)f(ri|yi,wi,ϑ),
where f(yi|xi, zi,θ) is the marginal density of the measurement process while
f(ri|yi,wi,ϑ) is the density of the missingness process that is dependent on the
responses (yi). The f(ri|yi,wi,ϑ) component can be considered as a proba-
bilistic mechanism that describes a patient’s self-selection with regards to either
withdrawing or staying the study (Rizopoulos, 2012).
Pattern mixture models define a full dataset density of
f(yi, ri|xi, zi,wi,θ,ϑ) = f(yi|ri,xi, zi,θ)f(ri|wi,ϑ).
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In this model the responses are modeled conditionally on the missingness pro-
cess, while the missingness process can be modeled directly without considering
the responses. As a result there is allowance for a different measurement model
with each pattern of missing responses.
Shared-parameter models capture the association between measurement and
missingness processes through the use of random effects. This leads to a full
dataset density of
f(yi, ri|xi, zi,wi,θ,ϑ) =
∫
f(yi|xi, zi,θ,bi)f(ri|wi,ϑ,bi)dbi.
It is thus assumed that the measurement and missingness processes are inde-
pendent given a latent random effect structure bi. Shared-parameter models
will be used for the remainder of this analysis.
As discussed in the previous chapter informative censoring may have oc-
curred in this study, which implies that a MNAR mechanism may apply to the
data used in this thesis. Authors like Guo and Carlin (2004), Rizopoulos (2012)
and Ibrahim et al. (2001) showed that joint models can be used to model infor-
mative dropout, where the survival time was taken as the time to dropout. The
joint density function for the observed longitudinal and survival data is given
as







where di is an indicator for the time to dropout. It is evident from Equation
44 that the measurement and dropout processes are conditionally independent
given the random effects bi.
In this analysis joint models will be used to impute the incomplete game-
tocyte profiles. These joint models will combine the longitudinal gametocyte
profiles with the survival model attributed to the time to early exit from the
study. As shown above this method will accommodate the informative censor-
ing associated with the study. The types of joint models that were used in this
analysis will be described in the following sections.
4.4 Normally distributed nonlinear joint models
4.4.1 Nonlinear mixed effect models
Nonlinear mixed effect models are an extension of the widely used linear mixed
effects models. They are used to model longitudinal (repeated measures) data.
These models allow the conditional expectation of the response variable, given
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random effects, to be a nonlinear function of model coefficients. The formula-
tion of the nonlinear mixed effects model presented in this section was initially
proposed by Lindstrom and Bates (1990). This formulation was generalized by
Pinheiro and Bates (2000) in order to accommodate time varying covariates.
The generalized formulation of this model, adapted for this analysis, can be
described using the equation below
yij = f(θi,xi, sij) + eij , (45)
where
• The mean response is given by f(θi,xi, sij).
• f is a nonlinear function of the observed covariates.
• sij is the patient observation day.
• eij is the within group error term that is assumed to follow a normal
distribution given as eij ∼ N(0, σ2e) with σ2e being the variance of the
error term.
• σ2e is equivalent to τ−1e , where τe is the precision parameter.
The parameter vector θi is defined as
θi = Aiβ + Bibi,
where bi is a m-dimensional vector of random effects linked to the i
th subject.
These random effects are assumed to follow a normal distribution given by
bi ∼ N(0,ψ) with ψ being the variance-covariance matrix; β is a p-dimensional
vector of fixed effects. The matrices Ai and Bi are design matrices for the fixed
effects and the random effects respectively. It is assumed that the within-group
errors (eij) are independently distributed and that they are independent of bi.
A further assumption is that observations corresponding to different groups are
independent of each other. A more detailed review of nonlinear mixed effect
models is provided by Pinheiro and Bates (2000).
As illustrated in Chapter 1, the gametocyte longitudinal profile has a non-
linear relationship with time. In this thesis the modified critical exponential
nonlinear mixed effect model was applied to capture the shape of the longitu-
dinal profile. Distiller et al. (2010) identified this as an appropriate model to
illustrate the gametocyte profile. Assuming that yij ∼ N(µij , τ−1e ), the critical
exponential model can be defined as
E[yij |bi] = µij
















• {xTAi,xTCi,xTRi} being a set of observed explanatory variables for the com-
ponents {Aij , Cij , Rij}, where the different components are allowed to
have different explanatory variables.
• {βA,βC ,βR} are the fixed effects for the different model components.
• {bAi, bBi, bCi} are the random effects for the different model components.
Since only baseline covariates were considered in this analysis, it follows that
{Aij , Cij , Rij} is equivalent to {Ai, Ci, Ri}.
In this analysis patients who entered the study had no gametocytes at day
0, as a result it can be seen that the Ai parameter would not be required. The
modified critical exponential model is a simplification of Equation 46, whereby
the Ai component is removed from the model. As a result the modified critical
exponential model is given as
µij = [Ci × sij ]× [R
sij
i ]. (47)
This formulation gives an expected value of 0, on day 0, which is consistent
with the underlying data. Figure 26 illustrates the various shapes that the
model can take, across varying values of the C and R components. These
plots are superimposed onto the observed mean gametocyte profiles for patients
receiving sulfadoxine-pyrimethamine (SP) treatment. Figure 27 illustrates how
the C (set to 0.8) and R (set to 0.91) components combine to give the shape of
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Figure 26: Shapes of the modified critical exponential Model by varying C and
R parameters: R = 0.89 (Red line) , R = 0.90 (Green line), R = 0.91 (Blue line)
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Figure 27: Build-up of the modified critical exponential Model for C = 0.8 and
R = 0.91, with the circles representing the mean gametocyte profile for patients
receiving SP treatment
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4.4.2 Extension to a normally distributed nonlinear joint model
In this section the nonlinear mixed effect model, outlined above, was extended
to a joint model that combined the longitudinal gametocyte profile to the time
to early exit survival model. The longitudinal component of the model can be
defined as
yij |bi ∼ N(µij , τ−1e ),
where




Ci = βC0 + (trti × βC1) + (ratioi × βC2) + (anaemiai × βC3) + (mut5i × βC4)
+ (lagei × βC5) + (pzeroi × βC6) + (genderi × βC7) + ci
and
Ri = βR0 + (trti × βR1) + (ratioi × βR2) + (anaemiai × βR3) + (mut5i × βR4)
+ (lagei × βR5) + (pzeroi × βR6) + (genderi × βR7) + ri.
The random effects ci and ri (collectively referred to as bi) are assumed to
follow normal distributions such that ci ∼ N(0, τ−1c ) and ri ∼ N(0, τ−1r ). Non-
informative prior distributions were applied to both the fixed and random effects
of the longitudinal component of the model. The fixed effects were assumed to
follow normal distributions such that βCl ∼ N(0, 10000) and βRl ∼ N(0, 10000)
∀l = 1, . . . , 7. The precision parameters and random error were all assumed to
follow a gamma distribution such that τk ∼ Γ(0.001, 0.001) ∀k = c, r, e.
The survival component of the model was assumed to be either a standard
exponential or Weibull parametric model. These models were described in detail
in Chapter 3.
Assuming that the time to early exit (ti) follows a Weibull distribution,
such that ti ∼ W (ρ, λi), with ρ as the shape parameter that is greater than
zero and that the same baseline covariates applied in the longitudinal submodel
were applied to the survival submodel; the following parametric survival model
applies
log(λi) =β0 + (trti × β1) + (ratioi × β2) + (anaemiai × β3) + (mut5i × β4)
+ (lagei × β5) + (pzeroi × β6) + (genderi × β7) + (ωc × ci) + (ωr × ri),
(48)
where ci and ri are the same random effects applied in the longitudinal model,
with ωc and ωr as parameters that measure the strength of the association
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between the survival and longitudinal components of the joint models. The
same non-informative prior distributions, applied to the fixed effects used in
the longitudinal model, were applied to the fixed effects given in Equation 48;
including the ωc and ωr parameters. The shape parameter, ρ, was assumed to
follow a uniform distribution such that ρ ∼ U(0, 100). The above result can be
simplified to an exponential model by setting ρ = 1.
The two components, outlined above, are connected through the use of com-
mon random effects in both components of the model. The parameters, ωc and
ωr, are used to scale the random effects in the survival model. The ωc and ωr
parameters can thus be seen to be jointly estimated from both components. A
further connection between the two components arises from the use of common
covariates across both components.
The likelihood function for the joint model specified above can be expressed
in the following manner. Consider it given that, y and t are representative
of the observed longitudinal and survival data, whereby t also accommodates
the indicator variable that specifies whether a patient exited the study or not.
In addition it is given that βy and βt represent the fixed effect parameters
for these components of the data respectively. Additionally b represents the
random effect parameters applied in the model with Σ as the corresponding
covariance matrix for these effects. The likelihood function for the joint model
(ignoring covariates for simplicity) is given as
π(βy,βt,b,ω,Σ, τe|y, t) ∝ π(y|βy,b,Σ, τe)× π(t|βt,ω,b,Σ)× π(βy)
× π(βt)× π(b|Σ)× π(Σ)× π(ω)× π(τe).
(49)
















where µij is as defined in Equation 47 and y is assumed to be normally dis-
tributed.
Assuming that the Weibull survival model is applied, the corresponding sur-





δi exp{−λitρi } (51)
where δi is an indicator value that takes a value of 1 when a patient exits the
study and 0 otherwise and λi is as defined in Equation 48. This contribution
can be simplified to give the contribution for the exponential model by set-
ting ρ = 1. In addition this contribution can be extended to accommodate
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cause-specific risks using the methodology outlined in Chapter 3.3. The result-
ing cause-specific risks survival submodel contribution is thus an extension of







δki exp{−λkitρki }, (52)
where h represents the set of distinct causes of early exit, that is loss-to-follow-
up or treatment failure, with δki as an indicator variable that gives a value of 1
when the kth cause of exit occurs and 0 otherwise. In addition βt is extended
to accommodate the fixed effect parameters for both causes of early exit from
the study.
The models outlined above are able to account for the overarching shape of
the gametocyte profile. However, they do not account for the large number of
zero values in the data. In the proceeding section a model that is able account
for the zero-inflation in the data will be outlined.
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4.5 Zero-adjusted gamma nonlinear joint models
4.5.1 Zero-adjusted gamma nonlinear mixed effects model
The gametocyte data used in this analysis was found to be zero-inflated, as the
majority of observed responses had zero values. This can be seen in Figure 28,
where the distribution of the gametocyte density is illustrated for patients who
received sulfadoxine-pyrimethamine (SP) treatment only and for patients who
received a combination of artesunate and sulfadoxine-pyrimethamine (ACT)
treatment. It can be seen that more than 80% of the observed responses were
zeros, across both treatments, with 97% of the observations collected from pa-







































Figure 28: Distribution of log2 gametocyte density by treatment
Zero inflated data, of this nature, is fairly common in both industrial data
(Lambert, 1992) and epidemiological data (Hall, 2000). Extensive work has
been done in modeling zero inflated count data using discrete mixture mod-
els. Examples of these models include hurdle models (Mullahy, 1986, Heilbron,
1989), which comprise of a mixture of a point mass at zero combined with a
truncated discrete count model for values greater than zero.
The zero inflated model (Heilbron, 1994, Lambert, 1992) is an alternative
model that can used. It comprises of a mixture of a point mass at zero and an
untruncated discrete count model. A key characteristic of this type of model is
that zero values are included in both parts of the mixture model. This allows
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for zeros to be categorized as “structural” (zeros that are imposed due to the
design of the experiment) and “chance” (zeros that occur randomly) (Neelon
et al., 2010). Zero deflation cannot be accommodated by such models as the
probability of structural zeros is non-negative. Examples of such models are
the zero inflated Poisson model and the zero inflated negative binomial model.
Ridout et al. (1998) provides an in-depth overview of zero inflated models.
Bayesian approaches to fitting zero-inflated data have beeen well documented
in literature. Ghosh et al. (2006) developed Bayesian zero-inflated Poisson mod-
els for cross-sectional data. This approach involved the use of Markov chain
Monte-Carlo simulations with a “data augmentation” step (Tanner and Wong,
1987), which allowed the authors to obtain posterior samples. Neelon et al.
(2010) presented a Bayesian modeling approach for repeated measures zero-
inflated count data, which allowed for correlated random effects in both parts
of the mixture model.
In this study the non-zero data was considered as being continuous. As
a result, a “zero-adjusted” model was applied to the data as opposed to a
“zero-inflated” model. A zero-adjusted model combines discrete and continu-
ous distributions. The discrete component of the model applies the Bernoulli
distribution to account for the probability of gametocytemia. The continuous
component of the model accounts for the non-zero values in the data, which
were assumed to follow a gamma distribution. This type of model is referred
to as a zero-adjusted gamma model (ZAG). A variation of the three parameter
ZAG, defined by Rigby and Stasinopoulos (2010), is outlined below
f(yij |µij , τ, pij) =

1− pij if yij = 0
pij ×







if yij > 0,
where pij is the probability that gametocytes are present. It follows that 0 <
pij < 1, µij > 0 and τ > 0; where τ =
1
σ2 , with σ as the dispersion parameter.
The properties of this distribution are
• E(Yij |bi) = pijµij
• Var(Yij |bi) = pijµ2ij{(1− pij) + 1τ }.
This model can be applied using the Generalized Additive Models for Loca-
tion, Scale and Shape (GAMLSS) framework proposed by Rigby and Stasinopou-
los (2005). This framework is very flexible and it can be applied to a wide range
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of distributions, including distributions that are not part of the exponential
family of distributions.
The ZAG model outlined above can be extended to allow for covariates and
random effects under a mixed effect regression framework. Using the predefined
notation given at the start of this chapter, the two components of the ZAG
regression model are defined as
logit(pij |b1i) = g(x1i,b1i,θ1) (53)
and
log(µij |b2i) = h(x2i,b2i,θ2), (54)
where pij is the probability that gametocytes are present, with g and h as
nonlinear functions, xki (∀k = 1, 2) are covariate vectors, θk (∀k = 1, 2) are
vectors of fixed effect coefficients and bki (∀k = 1, 2) denote random effect
parameters. In this investigation the same set of covariates were applied in
the Bernoulli and gamma components of the model, thus xki can be replaced
with xi in the above formulation. The covariates in the two aforementioned
components can be allowed to differ when there is a prior scientific reason to
believe that the covariates are different or if the aim of the investigation is to
find the most parsimonious model, which would arise due to extensive model
building (Neelon et al., 2010). In this investigation, no model building will be
applied as the aim is to compare different joint models using the same set of
covariates. It will also be assumed that only random intercepts are required to
capture the heterogeneity between patients in the study. The implication of this
assumptions is that b1i = b1i and b2i = b2i.
Prior distributions for parameters are a requirement when undertaking a
Bayesian analysis. The fixed effects in this analysis are assumed to have an
independent, multivariate normal prior distribution such that
θk ∼ Np(θ0, σ2θIs),
where θ0 and σ
2
θ are known hyper-parameters with Is as a s×s identity matrix.
The prior distribution applied to the random effects was a bivariate normal















Alternative prior distributions can be applied to the random effects. These
include the diffuse inverse-Wishart distribution (Neelon et al., 2010) and the
product normal parameterization for the random effects (Spiegelhalter, 1998,
Cooper et al., 2007). In this analysis the simplified covariance structure, given
above, was applied as it allowed for easy comparison across the models fit in
this analysis.
Assuming prior independence, the joint posterior distribution of the model























where π(y|.) is the likelihood for the data (y) given the model parameters, with
dij as a indicator variable with a value of 1 when gametocytes are present and
0 otherwise; π(θ1),π(θ2),π(Σ) are prior densities for θ1,θ2 and Σ.
Equations 53 and 54 introduced two nonlinear functions, g and h, which
would be required to fit the zero-adjusted gamma (ZAG) model. These func-
tions, g(.) and h(.), would affect the prevalence and gamma distributed compo-
nents of the model respectively. These functions would have to accommodate
the nonlinear profiles of the prevalence of gametocytemia as well as the non-
linear nature of the observed gametocyte profiles. It has already been shown
that the modified critical exponential model provides an appropriate represen-
tation of the nonlinear relationship between gametocyte density and time. As
a result it would be expected that the functions to apply in the zero-adjusted
gamma analysis would be based on the modified critical exponential model.
Unfortunately the modified critical exponential model cannot be used when
modeling the prevalence and gamma components of the ZAG model. This is




) while the gamma component would give an expected
density of 1 (= exp([Ci×0]× [R0i ]). This is not a desirable result as the patients
analyzed in this study did not have gametocytes on day 0. It is clear that in
both cases there is a need for an additional component to be included in the
model, which can make an adjustment to the predicted profiles at day 0. This
requirement led to the use of the previously described critical exponential model
101
(Equation 46). As a result the prevalence model that was applied is defined as
logit(pij |b1i) = g(x1ij ,b1i,β1)






exp{BAi + [(BCi × sij)×BR
sij
i ]}





BAi = βBA0 + (trti × βBA1) + (ratioi × βBA2) + (anaemiai × βBA3) + (mut5i × βBA4)
+ (lagei × βBA5) + (pzeroi × βBA6) + (genderi × βBA7),
with
BCi = βBC0 + (trti × βBC1) + (ratioi × βBC2) + (anaemiai × βBC3) + (mut5i × βBC4)
+ (lagei × βBC5) + (pzeroi × βBC6) + (genderi × βBC7) + bci,
and
BRi = βBR0 + (trti × βBR1) + (ratioi × βBR2) + (anaemiai × βBR3) + (mut5i × βBR4)
+ (lagei × βBR5) + (pzeroi × βBR6) + (genderi × βBR7) + bri.
It follows that b1i refers to the random effects bci and bri. It is evident that no
random effects were placed on the BA component of the model. This is because
any random patient level variation in the upward trajectory of the gametocyte
profile, can be sufficiently accommodated by the BC component of the model.
At the same time the patient level variability in the downward trajectory is
accounted for by the BR component.
The different shapes of the critical exponential model, for the prevalence
model, are shown in Figure 29. In addition Figure 30 gives a graphical rep-
resentation of the transformation steps that give the predicted probability of
gametocytemia. This figure gives the profile of BAi+ [(BCi× sij)×BR
sij
i ] and
subsequently the impact of taking the exponent of that profile before finally
converting it into a probability.
The critical exponential model was also applied to the gamma distributed
component of the ZAG model. The resulting model is given as




Ai = βA0 + (trti × βA1) + (ratioi × βA2) + (anaemiai × βA3) + (mut5i × βA4)
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Figure 29: Shapes of the critical exponential model for the prevalence of gameto-
cytemia by varying BC and BR parameters (BR = 0.92 (Red line), BR = 0.93
(Green line), BR = 0.94 (Blue line)), with BA set to -4; where the circles
represent the observed prevalence of gametocytemia for patients receiving SP
treatment.
with
Ci = βC0 + (trti × βC1) + (ratioi × βC2) + (anaemiai × βC3) + (mut5i × βC4)
+ (lagei × βC5) + (pzeroi × βC6) + (genderi × βC7) + ci
and
Ri = βR0 + (trti × βR1) + (ratioi × βR2) + (anaemiai × βR3) + (mut5i × βR4)
+ (lagei × βR5) + (pzeroi × βR6) + (genderi × βR7) + ri,
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Figure 30: Build up of the critical exponential model for prevalence of gameto-
cytemia where BA = -4, BC = 0.7 and BR = 0.93 with the circles representing
the observed prevalence of gametocytemia for patients receiving SP treatment.
model, no random effects were placed on the A component of the model.
The various shapes of the critical exponential model for the gamma compo-
nent of the zero-adjusted gamma (ZAG) model are shown in Figure 31, with
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Figure 31: Shapes of the critical exponential model for the gamma distributed
continuous component of the ZAG model by varying C and R parameters: R =
0.91 (Red line), R = 0.92 (Green line), R = 0.93 (Blue line) with A = -1 and
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Figure 32: Build up of the critical exponential model for the gamma distributed
continuous component of the ZAG model where A = -1, C = 0.475 and R = 0.92
with the circles representing the mean gametocyte profile for patients receiving
SP treatment.
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4.5.2 Extension to a zero-adjusted gamma nonlinear joint model
The zero-adjusted gamma (ZAG) model outlined above can be extended to a
joint model that combines the longitudinal gametocyte profile with the time to
early exit survival model. The longitudinal component of the model is split into
a prevalence component and a continuous component as previously shown by
Equations 57 and 58 respectively.
The random effects bci and bri (collectively referred to as b1i), along with ci
and ri (collectively referred to as b2i) are assumed to follow normal distributions.
This implies that bci ∼ N(0, τ−1bc ) , bri ∼ N(0, τ
−1
br ), ci ∼ N(0, τ−1c ) and ri ∼
N(0, τ−1r ). Non-informative prior distributions were applied to both the fixed
and random effects of the longitudinal component of the model. The fixed
effects were assumed to follow normal distributions such that βCl ∼ N(0, 10000),
βRl ∼ N(0, 10000), βBCl ∼ N(0, 10000) and βBRl ∼ N(0, 10000) ∀l = 1, . . . , 7.
The random effects and random error were all assumed to follow a gamma
distribution such that τk ∼ Γ(0.001, 0.001) ∀k = c, r, bc, br, e.
The survival model, shown in Equation 48, was extended to accommodate
the prevalence random effects such that it became
log(λi) =β0 + (trti × β1) + (ratioi × β2) + (anaemiai × β3) + (mut5i × β4)
+ (lagei × β5) + (pzeroi × β6) + (genderi × β7)
+ (ωc × ci) + (ωr × ri) + (ωbc × bci) + (ωbr × bri),
(59)
where ci, ri, bci and bri are the same random effects applied in the longitudinal
model, with ωc, ωr, ωbc and ωbr as parameters that measure the strength of
the association between the survival and longitudinal components of the fitted
joint models. The same non-informative prior distributions, applied to the fixed
effects used in the longitudinal model, were applied to the fixed effects given in
Equation 59. The shape parameter, ρ, is assumed to follow a uniform distribu-
tion such that ρ ∼ U(0, 100). The Weibull survival model, given above, can be
simplified to an exponential model by setting ρ = 1.
By applying the same notation as that used in the previous section it fol-
lows that, the likelihood function for the joint model (ignoring covariates for
simplicity) specified above is given as
π(βy,βt,b,ω,Σ, τ |y, t) ∝ π(y|βy,b,Σ, τ)× π(t|βt,ω,b,Σ)× π(βy)
× π(βt)× π(b|Σ)× π(Σ)× π(ω)× π(τ).
(60)
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where µij and pij are as previously defined in Equations 57 and 58.
Assuming that the Weibull model is applied, the corresponding survival sub-





δi exp{−λitρi }, (62)
where δi is an indicator variable having a value of 1 if exit occurs and 0 otherwise.
The survival submodel provided above can also be extended to accommodate








where h represents the set of distinct causes of early exit, that is loss-to-follow-
up or treatment failure, with δki as an indicator variable that gives a value of
1 when the kth cause of exit occurs and 0 otherwise; in addition βt is extended




The models outlined above were computed using the Gibbs sampling MCMC
algorithm. This algorithm iteratively samples from the full conditional distri-
butions of the parameters used in the models. The Gibbs sampling algorithm
was implemented using JAGS (Plummer, 2003), through the jagsUI (Kellner,
2016) package in R (R Core Team, 2015).
The zero-adjusted gamma (ZAG) distribution is not a pre-designated distri-
bution in JAGS, thus a likelihood for the distribution needed to be defined as
part of the fitting process. This was done by applying the “zeros trick” that
is defined in Spiegelhalter et al. (2003). This trick converts the likelihood con-
tributions for the observed data into a format that can be processed by JAGS.
Given that responses (yij) follow a ZAG distribution, with each observation
contributing a likelihood term Lij , the “zeros trick” would involve the creation
of a dummy set of observations (zij) with values of zero, which are assumed
to follow a Poisson distribution with mean ψij . The associated likelihood con-
tributions for these dummy values would be exp(−ψij). Setting ψij equal to
− logLij would result in JAGS processing the correct likelihood contribution
for yij . Since ψij should always be greater than 0, a large positive value is
usually included in the formulation of ψij such that
ψij = − logLij + C,
where C was considered as 1000 in this analysis.
The same modeling strategy was applied to all fitted models in this analysis,
to allow for consistency in approach. This strategy involved initializing three
chains with 30 000 iterations for each chain, with 15 000 of these iterations being
considered as burn-in iterations. In order to reduce autocorrelation “thinning”
was applied. This involved retaining only the 10th value of each chain as part of
the estimation procedure. The median of the posterior samples was used as the
point estimate of the parameters fitted in this chapter, with the 2.5 and 97.5
percentiles of the posterior samples used as the 95% credibility interval.
4.7 Model selection
In this analysis no variable selection was conducted, as this would have made
it difficult to compare the different model structures fit to the data. The only
selection process implied in this analysis was based on determining the most
appropriate underlying model structure, based on a fixed set of covariates. The
covariates used in this analysis were
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• log10 baseline asexual parasite density (pzero).
• Prevalence of quintuple mutations (mut5), defined as 1 for presence and
0 for absence of quintuple mutations.
• Treatment, defined as sulfadoxine-pyrimethamine treatment only (SP) or
a combination of artesunate and sulfadoxine-pyrimethamine (ACT) (trt).
SP was given a value of 0 and ACT was given a value of 1.
• Parasite reduction ratio at 24 hours (ratio).
• Gender of patient, with males given a value of 1 and females given a value
of 0 (gender).
• Prevalence of moderate anaemia (anaemia), where moderate anaemia
was defined as having a haemoglobin density less than 11g/dL. Patients
with moderate anaemia were given a value of 1 while patients with a
haemoglobin density greater than 11g/dL were given a value of 0.
• log2 of patient age (in years) (lage).
There are several procedures that can be used to determine the optimal
model, from a set of models developed as part of the model building stage of
an analysis. One such procedure involves taking an average of all posterior
probabilities that each one of the fitted models is the true model and then
subsequently obtaining posterior parameters (Hoeting et al., 1999). This type
of method is computationally intensive as it requires the use of procedures that
can provide coverage for the entire model space, an example being the reversible
jump MCMC (Green, 1995).
Another method involves assessing the ratios of posterior probabilities from
competing models. These ratios are called Bayes factors (Kass and Raftery,






where y is a vector of observed data, with π(y|M0) and π(y|M1) as the marginal
likelihoods of y under the respective models. It is important to note that Bayes
factors require the use of proper priors (Neelon et al., 2010).
In this analysis the deviance information criterion (DIC) was used as a model
adequacy and goodness of fit measure. It was proposed by Spiegelhalter et al.
(2002) as a Bayesian model selection tool. This measure is similar to the Akaike
information criterion (AIC) and Bayesian information criterion (BIC), which
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are both measures commonly used under the frequentist framework. The DIC
applies a penalty to offset the gains in a model fit that arise due to an increase
in the complexity of a model, this is similar to the approach applied by the
AIC and BIC. It is fairly straight-forward to determine the complexity of the
fixed effects in a model as this is defined as the number of model parameters.
The same cannot be said when trying to assess the complexity of the random
effects. The impact of random effects, on the number of model parameters, is
determined by the variance of these effects. Random effects with a large variance
contribute approximately one parameter while random effects with a very small
variance contribute approximately zero parameters (Elliott et al., 2005). The
DIC is able to estimate the effective number of parameters in a fitted mixed
effect model. The DIC for a model M is defined as
DIC(M) = 2D(θm,M)−D(θm,M)
= D(θm,M) + 2pm
(63)
where θm is a vector of model parameters used in model M , y is a vector of
observed data, D(θm,M) is the Bayesian deviance defined as
D(θm,M) = −2 log[π(y|θ,M)],
θm and D(θm,M) are the means of the posterior distributions of θm and
D(θm,M) respectively, pm is the number of effective parameters defined as
pm = D(θm,M)−D(θm,M).
The effective number of parameters (pm) is a measure of model complexity,
which penalizes the measure of the goodness of fit. A model with the lowest
DIC is considered the best fitting model.
In this analysis the “zeros trick” was applied to fit the ZAG model using
JAGS. This approach derives the DIC on a different scale to that used by built-
in distributions in JAGS. Therefore, the DIC statistics produced from fitting
the ZAG models would need to be adjusted in order to compare them to those
derived from models that were fit whilst ignoring the zero-inflation in the data.
The methodology used to make this adjustment was outlined by Lunn et al.
(2012) and it is shown below.
Given that the Bayesian deviance, derived using the “zeros trick” (Dzero)
refers to a Poisson model with dummy data made up of zero values, that is









As part of the model fitting process, ψij is defined as
ψij = C − log[g(yij |θ)],
with g(yij |θ) as the sampling distribution for the ZAG response and C as a
large constant value (set as 1000 in this analysis) that ensures that ψij remains
positive. It follows that Equation 64 can be simplified to
f(zij |ψij) = e−C+log[g(yij |θ)]
= e−Cg(yij |θ).
(65)
Both sides of Equation 65 can be converted into Bayesian deviances by taking












Dzero = 2mniC +D,
(66)
where D is the Bayesian deviance measured on the scale of the observed data
yij . It thus follows that the DIC on the zero scale is different to the DIC on the
observed data scale by a value of 2mniC. This value will be removed from the
DIC extracted from JAGS, when comparing the goodness of fit of the models
applied.
An additional goodness of fit test is based on the predictive loss function.
This function compares the observed with the predicted response. Laud and
Ibrahim (1995) and Gelfand and Ghosh (1998) proposed the use of the poste-
rior predictive loss (PPL) and mean square predictive error (MSPE). In this
analysis the MSPE will be used. Given an observed response yij and its corre-
sponding predicted value ỹij , which is a simulation from the posterior predictive









The median of the generated MSPE statistics was used as a point estimate, with
the 2.5 and 97.5 percentiles used as the 95% credibility interval.
112
4.8 Model checking
Once the optimal model was selected, the fit of the model to the observed
data was assessed. This was done by assessing the posterior distribution of
standardized Pearson residuals, from the selected model. These residuals were
used to assess the deviation between observed and predicted values. They are
defined as
rij =
yij − E(yij |θ)√
V ar(yij |θ)
,
with large values of rij indicating a poor model fit. It is assumed that
rij ∼ N(0, 1),
thus rij values would be expected to lie between -2 and 2 if a fitted model is ap-
propriate. The median of the simulated distribution of residuals can be plotted
against the median fitted values in order to assess model adequacy. Systematic
trends in the plot would indicate that the plot was not appropriate. Pearson
residuals can also be derived for the missing observations. These residuals are
derived as
rmij =
ymij − E(ymij |θ)√
V ar(ymij |θ)
,
where rmij are the standardized Pearson residuals for the missing data, y
m
ij are
the imputed responses produced as part of the MCMC estimation procedure
with E(ymij |θ) as the fitted values attributed to the missing observations. As-
suming that ymij follows a normal distribution with E(y
m
ij |θ) = f(θi,xi, smij ), the
response ymij is defined as
ymij = f(θi,xi, s
m
ij ) + eij
where eij is the within group error term as defined in Equation 45 and s
m
ij is
the observation day associated with the missing value.
4.9 Imputation of incomplete gametocyte profiles
The main aim of fitting the joint models, derived earlier in this chapter, was
to impute the incomplete gametocyte profiles for patients who exited the study
early. This was achieved through the use of the posterior samples generated
as part of the Bayesian MCMC procedure. Once complete gametocyte profiles
have been developed, they can be used to investigate clinical research questions
like the estimation of the duration of gametocytemia or the area under the
curve (AUC) of the gametocyte profile. It was highlighted in Chapter 3 that
the data used in this analysis was affected by interval censoring. The imputation
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of incomplete gametocyte profiles mitigates the effect of interval censoring as
predicted responses can be generated for the timepoints that lie in between the
study’s predefined observation dates. In this thesis the imputed gametocyte
profiles were used to extend the analysis into the duration of gametocytemia,
which was previously discussed in Chapter 3.
The methodology used to impute the incomplete gametocyte profiles and
subsequently estimate the duration of gametocytemia is outlined below. The
methodology will be outlined for a ZAG joint model with a time to early exit
survival component that assumes that time follows an exponential distribution.
The methodology applied proceeded as follows, given that the survival com-
ponent of the joint model was defined as
log(λi) =β0 + (trti × β1) + (ratioi × β2) + (anaemiai × β3) + (mut5i × β4)
+ (lagei × β5) + (pzeroi × β6) + (genderi × β7)
+ (ωc × ci) + (ωr × ri) + (ωbc × bci) + (ωbr × bri),
with the prevalence component of the longitudinal model defined as




BAi = βBA0 + (trti × βBA1) + (ratioi × βBA2) + (anaemiai × βBA3) + (mut5i × βBA4)
+ (lagei × βBA5) + (pzeroi × βBA6) + (genderi × βBA7),
with
BCi = βBC0 + (trti × βBC1) + (ratioi × βBC2) + (anaemiai × βBC3) + (mut5i × βBC4)
+ (lagei × βBC5) + (pzeroi × βBC6) + (genderi × βBC7) + bci
and
BRi = βBR0 + (trti × βBR1) + (ratioi × βBR2) + (anaemiai × βBR3) + (mut5i × βBR4)
+ (lagei × βBR5) + (pzeroi × βBR6) + (genderi × βBR7) + bri.
In addition the gamma component was defined as




Ai = βA0 + (trti × βA1) + (ratioi × βA2) + (anaemiai × βA3) + (mut5i × βA4)
+ (lagei × βA5) + (pzeroi × βA6) + (genderi × βA7)
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with
Ci = βC0 + (trti × βC1) + (ratioi × βC2) + (anaemiai × βC3) + (mut5i × βC4)
+ (lagei × βC5) + (pzeroi × βC6) + (genderi × βC7) + ci
and
Ri = βR0 + (trti × βR1) + (ratioi × βR2) + (anaemiai × βR3) + (mut5i × βR4)
+ (lagei × βR5) + (pzeroi × βR6) + (genderi × βR7) + ri.
After a sufficient burn-in period, L iterations were used to generate the posterior
samples used in this analysis. After each iteration l (∀l = 1, . . . , L) the following
occurred.
1. Posterior draws for β
(l)
hk (∀h = A,C,R,BA,BC,BR and ∀k = 1, . . . 7)









2. The fixed and random effect posterior draws given above were subse-












i , using the
respective linear predictors given as part of the joint model formulation

















ij for any timepoint (sij). This
was achieved using the relationship
pij |b1i =
exp{BAi + [(BCi × sij)×BR
sij
i ]}












ij estimates were then be used to derive the expected ga-






ij . In this section the j was considered to range
from day 0 to 100, with daily increments.
The process above was repeated L times until L complete datasets were gener-
ated for the patients in the study. In each iteration a subset of patients who were
considered to have gametocytemia was taken. Since male and female gameto-
cytes are required for the lifecyle of the parasite to continue, it was assumed in
this thesis that gametocytemia would occur if a count of more than two game-
tocytes was predicted; this is equivalent to having an expected logarithm to the
base two gametocyte density of at least 1. Subsequently L Weibull AFT models
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for the time to gametocyte clearance were fit to those subsets with the model





0 + (trti × α
(l)
1 ) + (ratioi × α
(l)
2 ) + (anaemiai × α
(l)
3 ) + (mut5i × α
(l)
4 )
+ (lagei × α(l)5 ) + (pzeroi × α
(l)





i is the estimated time to gametocyte clearance for the i
th patient dur-
ing the lth iteration with α
(l)
k (∀k = 1, . . . , 7) as the fixed effect AFT parameters
calculated during the lth iteration . These generated parameters were consid-
ered as a pseudo posterior distribution for the resulting Weibull AFT parameters
arising from the joint modeling procedure. At this stage these generated param-
eters could be used to make predictions on the duration of gametocytemia. The
medians of each of these generated AFT parameter samples were considered
as the point estimates for the parameters. The 2.5 and 97.5 percentiles, from
the generated samples, were used as the 95% credibility interval for the AFT
parameters. The same approach would be taken to derive the 95% credibility
interval for the estimated durations, derived for a generic group of patients with
specific covariate patterns, generated at each iteration.
The methodology outlined above would be able to provide duration estimates
for a subset of the population that would have experienced gametocytemia.
In order to extend these findings to provide population level estimates, based
on patient covariate patterns, the methodology associated with Equation 37
(discussed in Chapter 3) was applied. This approach required the development
of a baseline prevalence model for gametocytemia. A similar approach to the
one used to derive the Weibull AFT model point estimate parameters was taken
to derive the parameters for the baseline prevalence model. This approach
involved fitting a baseline gametocyte prevalence model during each iteration.





B0 + (trti × β
(l)
B1) + (ratioi × β
(l)
B2) + (anaemiai × β
(l)
B3) + (mut5i × β
(l)
B4)
+ (lagei × β(l)B5) + (pzeroi × β
(l)





i is the estimated prevalence to gametocytemia the i
th patient during
the lth iteration and β
(l)
Bk (∀k = 1, . . . , 7) are the fixed effect baseline prevalence
parameters calculated during the lth iteration.
The point estimates from the prevalence model and the survival model were
then used to derive an adjusted duration for generic patients with specific co-
variate patterns, as per Equation 37.
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4.10 Model fitting results
A range of joint models were fit to the data recorded in the study. These models
were split into those that ignored zero-inflation and those that accounted for
it. The differences, within each of these classes of models, was determined by
the definition of the survival component of the models. The types of survival
components used in this analysis were the exponential survival model, Weibull
survival model, exponential cause-specific model and the Weibull cause-specific
model. The definitions of each of the fitted models used in this analysis are
shown in Table 22.
Table 22: Definitions of the fitted Joint models.
Class of Joint models Label Description of survival component
Nonlinear joint that assumes that the
longitudinal response follows a normal
distribution (NL)
NLJ Exponential survival model
NLJW Weibull survival model
NLJC Exponential cause-specific model
NLJWC Weibull cause-specific model
Nonlinear joint models that assumes
that the longitudinal response follows
a zero-adjusted gamma distribution
(ZAG)
ZAGJ Exponential survival model
ZAGJW Weibull survival model
ZAGJC Exponential cause-specific model
ZAGJWC Weibull cause-specific model
The model fitting results of the survival components from the nonlinear joint
models that assume that the longitudinal response follows a normal distribution
(NL), are shown in Tables 23 and 24.
It can be seen from Table 23 that there is a strong association between
the survival and longitudinal components, across all the fitted joint models.
This is shown by the 95% CI of the association parameters not including 0.
When considering the NLJW (normally distributed nonlinear joint model with
a Weibull survival component) model, it is evident that the hypothesis that the
Weibull shape parameter is equal to 1 (implying an exponential distribution for
the survival component of the joint model) cannot be rejected as the 95% CI for
this parameter includes 1. Another interesting result is that the treatment effect
does not have an association with the hazard of time to early exit from the study.
This result may be due to combining the treatment failure and LTFU outcomes,
into a single outcome, as part of the formulation of the survival component of
the model.
117
Table 23: Model estimates (95% CI) for the survival component of the fitted
normally distributed nonlinear joint models.
Definition Parameter NLJ NLJW
Intercept β0 -8.702 (-10.471 ; -6.731) -9.123 (-13.491 ; -5.500)
trt β1 0.071 (-0.672 ; 0.786) 0.111 (-0.631 ; 0.957)
ratio β2 -1.182 (-1.951 ; -0.534) -1.325 (-2.431 ; -0.507)
anaemia β3 0.962 (0.260 ; 1.660) 0.777 (0.136 ; 1.572)
mut5 β4 1.383 (0.819 ; 1.999) 1.474 (0.843 ; 2.690)
lage β5 0.389 (0.022 ; 0.757) 0.287 (-0.053 ; 0.595)
pzero β6 0.057 (-0.012 ; 0.140) 0.064 (-0.024 ; 0.194)
gender β7 0.542 (0.012 ; 1.091) 0.459 (-0.075 ; 1.063)
Association parameters
ωc -0.863 (-1.204 ; -0.541) -1.102 (-1.843 ; -0.235)
ωr 3.786 (2.682 ; 4.976) 4.948 (1.349 ; 8.701)
Precision parameters
τc 0.577 (0.382 ; 0.806) 0.827 (0.538 ; 1.295)
τe 0.447 (0.415 ; 0.517) 0.493 (0.460 ; 0.536)
τr 5.178 (3.855 ; 8.110) 8.721 (6.344 ; 15.038)
shape ρ 1 1.144 (0.850 ; 1.702)
In Table 24 the treatment failure and LTFU outcomes, were analyzed sep-
arately as part of the cause-specific survival model. It can be seen that sepa-
rating these outcomes resulted in a strong association between treatment and
the relative hazards of both treatment failure and LTFU. The results from
both the NLJC (normally distributed nonlinear joint model with an exponential
cause-specific survival component) and NLJWC (normally distributed nonlin-
ear joint model with a Weibull cause-specific survival component) models im-
ply that receiving a combination of artesunate and sulfadoxine-pyrimethamine
treatment significantly decreases the hazard of treatment failure whilst signifi-
cantly increasing the hazard of LTFU. Barnes and White (2005) highlighted that
Plasmodiumfalciparum has developed clinically significant resistance to most
antimalarials when they are given alone (as monotherapy) and not combined
with an artemisinin derivative. As a result patients who receive a combination
of artesunate and sulfadoxine-pyrimethamine treatment would be expected to
clear the signs and symptoms associated with malaria infection at a faster rate
than those who receive sulfadoxine-pyrimethamine treatment only. Based on
the treatment effects highlighted above it appears as though patients who re-
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cover quickly are more likely to choose to exit the study, through LTFU, instead
of waiting for the completion of the study. The implication is that patients who
are LTFU are generally healthier than those who have to be rescued from the
study due to treatment failure.
Table 24 also reveals that the 95% credibility intervals for some of the as-
sociation parameters include 0, however in these cases the credibility interval is
predominately greater than or less than 0. This implies that there is evidence of
an association between the survival and longitudinal components of the fitted
cause-specific joint models. This in turn implies that there is a missing not
at random (MNAR) dropout mechanism associated with the data used in this
thesis.
The results of the longitudinal component of the fitted joint models are
provided in Table 25, along with their associated DIC and MSPE statistics. It
can be seen that model NLJWC (normally distributed nonlinear joint model
with a Weibull cause-specific survival component) had the lowest DIC statistic,
which would imply that it was the most appropriate model to apply. However
Figure 33, which provides a plot of residuals against fitted values, indicates
that there is a distinct systematic trend in the residuals of the fitted models.
This trend is due to the excess number of zero values in the data that are not
being accounted for. The implication of this result is that none of the normally





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 33: Standardized residual plots for the fitted normally distributed non-
linear joint models
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Zero-adjusted gamma joint models were fit to the data to account for the
observed zero-inflation. Table 26 provides the survival component parameter
estimates for the ZAGJ (zero-adjusted gamma nonlinear joint model with an
exponential survival component) and ZAGJW (zero-adjusted gamma nonlinear
joint model with a Weibull survival component) models.
It can be seen that the longitudinal component, of the ZAGJ model, has a
marginal association with the survival component through the ωbr parameter.
This is because the 95% CI for the ωbr parameter is be predominately negative.
All other association parameters attributed to this model indicate that there is
no association between the survival and longitudinal components, as shown by
0 being included the 95% CI for these parameters.
When considering the ZAGJW model, it is evident that there is a strong
association between the survival and longitudinal components of the joint model.
This is because the ωbr, ωc and ωr parameters all have 95% CIs that do not
include 0.
The strength of the association between the survival and longitudinal com-
ponents in the fitted ZAGJ and ZAGJW models imply that there is a missing
not at random (MNAR) dropout mechanism associated with the data used in
this thesis. The use of joint modeling techniques adjusts for this type of dropout,
leading to less biased parameter estimates.
The results from Table 26 indicate that combining the treatment failures
with the loss-to-follow-up outcomes, leads to treatment not having an associa-
tion with the hazard of early exit from the study. In addition it can be seen that
the hypothesis of the shape parameter being equal to 1, implying that an expo-
nential distribution should be assumed for the survival model, can be rejected






























































































































































































































































































































































































































































































































































































































































































































































The results of applying a cause-specific survival component, to the fitted joint
models, are shown in Table 27. This table compares the results of the ZAGJC
(zero-adjusted gamma nonlinear joint model with an exponential cause-specific
survival component) and ZAGJWC (zero-adjusted gamma nonlinear joint model
with a Weibull cause-specific survival component) models.
Table 27 reveals that treatment is strongly associated with both the hazard
of treatment failure and the hazard of loss-to-follow-up, with the 95% CI for the
treatment effect not including 0. The treatment effect indicates that receiving
a combination treatment of artesunate and sulfadoxine-pyrimethamine (ACT)
considerably decreases the hazard of treatment failure (78% reduction for the
ZAGJC model and 94% reduction for the ZAGJWC model) whilst increasing
the hazard of loss-to-follow-up (9 fold increase for the ZAGJC model and 289
fold increase for the ZAGJWC model). It can also be seen that resistance to
treatment, in the form of the presence of quintuple mutations (mut5), has a
strong association with the hazard of treatment failure. However, the mut5 ef-
fect did not have an association with the hazard of LTFU. An interesting finding
is that apart from patient gender, all the covariates used in this analysis had a
strong association (or marginal association in the case of the patient age when
considering the ZAGJWC model and baseline asexual parasite density when
considering the ZAGJC model) with the hazard of treatment failure. On the
other hand treatment (trt) was the only covariate that had a strong association
with the hazard of loss-to-follow-up. These findings apply to both the ZAGJC
and ZAGJWC models.
Table 27 provides an assessment of the association between the survival and
longitudinal components of the fitted ZAGJC and ZAGJWC models. When
considering the ZAGJC (zero-adjusted gamma nonlinear joint model with an
exponential cause-specific survival component) model, it can be seen that there
is a strong association between the survival component and the longitudinal
component of the joint model through the ωbrf , ωrf , ωbrl, ωcl and ωrl (marginal
association) parameters. The strong association between the survival compo-
nent and the longitudinal component of the ZAGJWC (zero-adjusted gamma
nonlinear joint model with a Weibull cause-specific survival component) model
arose through the ωbrf , ωbrl (marginal association), ωcl (marginal association)
and ωrl parameters. Once again it must be highlighted that this association in-
dicates that dropout was MNAR. Since this association arises when considering
both the treatment failure and LTFU causes of exit, it can be concluded that
both causes of exit are forms of informative censoring.
It can be seen, when considering the results of the ZAGJWC model fit shown
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in Table 27, that the 95% CI for the shape parameters associated with both
causes of early exit do not include 1. As a result it can be concluded that a
Weibull survival component is more appropriate as compared to an exponential
survival component. These findings support the use of the ZAGJWC model
over the ZAGJC model. The shape parameters for both causes of exit can be
seen to be greater than 1, thus implying that the hazards of treatment failure



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The model fitting results of the longitudinal components of the fitted mod-
els, along with their respective DIC statistics are provided in Table 28. It can
be seen that the ZAGJ and ZAGJC models had the lowest DIC statistics. The
MSPE was also used as an additional goodness of fit test, to determine that
zero-adjusted gamma joint model was more appropriate. The median MSPE
statistics derived for all the fitted models are fairly similar. However, the ZA-
GJW model can be seen to have the largest credibility range for the MSPE
statistic that would imply that this model is not appropriate.
Figure 34 provides a comparison of the plots of residuals against fitted values,
for the zero-adjusted gamma joint models fitted in this analysis. This figure
shows that, across all models, there were a small number of fairly large positive
residuals attributed to small fitted values. It is also evident from this figure that
the standardized residuals, across all the fitted models predominately ranged
between -2 and 2. In addition the systematic trend associated with the large
number of zero values in the data, which was previously an issue under the
normally distributed joint models, is no longer present. As a result it can be
concluded that all the models performed appropriately.
It was decided that the model that would be suitable for further investigation
was the ZAGJWC (zero-adjusted gamma nonlinear joint model with a Weibull
cause-specific survival component) model. The reasons for this were that firstly
the Weibull shape parameters were found to significantly different from 1, as
the 95% CI for these parameters (when considering the treatment failure and
loss-to-follow-up causes of exit) did not include 1. In addition the effect of the
treatment allocated to patients under this model provided clinically meaningful



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 34: Standardized residual plots for the fitted zero-adjusted gamma
(ZAG) joint models
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In order to graphically illustrate the predicted patient gametocyte profiles, a
generic patient dataset was created. This dataset allowed for the comparison of
specific covariates patterns. The covariate patterns were based on the following
covariate levels
• SP and ACT treatments
• “High” first 24 hour parasite reduction rate of 100% relative to a “Low”
first 24 hour parasite reduction rate of -31.4%
• Presence and absence of moderate anaemia
• Presence and absence of quintuple mutations
• “Old” patient with an age of 55.0 (lage = 5.781) and “Young” patient
with an age of 2 (lage = 1)
• “High” log10 baseline parasite density of 17.754 and “Low” baseline par-
asite density of 5
• Male and female patients
Based on the above characteristics a dataset of 128 distinct covariate patterns
was created. Subsequently the median fixed effect parameters from the fitted
ZAGJWC model (shown in Table 28) were used to create estimated gametocyte
profiles for these patients. This dataset allows for categories within covariates
to be compared in isolation, that it categories with-in a covariate can be allowed
to vary whilst all other covariates are held constant.
Figure 35 was created based on this approach and it allowed for the compar-
ison of the predicted profiles for a patient receiving a combination treatment of
artesunate and sulfadoxine-pyrimethamine and a patient receiving sulfadoxine-
pyrimethamine, whilst holding all other covariates at a constant value. It can be
seen from this plot that the predicted gametocyte profiles for patients receiving
SP treatment only are significantly higher than those for patients who received
a combination treatment of artesunate and sulfadoxine-pyrimethamine. It is of
interest to stratify the predicted profiles, of the other covariates considered, with
treatment to assess the level of impact that treatment has on the gametocyte
profiles relative to the other covariates. This is illustrated in Figure 36. It can
be seen that the application of artesunate sulfadoxine-pyrimethamine treatment
generally suppresses the magnitude of the predicted gametocyte density, regard-
less of the level of the associated covariate. The implication of these findings is
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Figure 35: Predicted gametocyte patient profiles by treatment, for the ZAGJWC
model































































































































































Figure 36: Predicted patient profiles by categorical covariates, stratified by
treatment, for the ZAGJWC model
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In order to assess the impact of informative censoring on parameter esti-
mates, a zero-adjusted gamma mixed effect model (ZAG) was fit to the longitu-
dinal data. The results of this model fit are shown in Table 29. This table also
provides a comparison with the parameters from the longitudinal component
of the ZAGJWC (zero-adjusted gamma nonlinear joint model with a Weibull
cause-specific survival component) model. It can be seen that there are no-
ticeable differences in the magnitude of the fixed effects across the ZAG and
ZAGJWC models. In some cases parameters that were found to have no as-
sociation with the longitudinal gametocyte profile under the ZAG model, were
found to have a strong association with the gametocyte profile once a ZAGJWC
model was applied. This finding applied to the βBC3 (moderate anaemia) , βBC5
(age) and βBC7 (gender) parameters.
A comparison of the predicted profiles arising from the ZAG and ZAGJWC
models, using the generic dataset previously created are shown in Figure 37.
This figure compares the profiles from the two models using set values for the
first 24 hour parasite reduction ratio grouped by the treatment administered. It
can be seen that the ZAG model generally predicted higher gametocyte densities
as compared to the ZAGJWC model.
The fitted values from the ZAG and ZAGJWC model fits were superimposed
onto the observed gametocyte profiles for select patients from the study (Figure
38). The patients in the top row of the plot were observed at all observation
points and thus had complete profiles. It is evident that the ZAGJWC predicted
profiles outperformed the ZAG across this group of patients. The remaining rows
provide examples of incomplete profiles (second row consisted of patients who
experienced treatment failure while the third row consisted of patients lost-to-
follow-up). The incomplete gametocyte profiles are superimposed with complete
predicted profiles from the ZAG and the ZAGJWC models. The profiles from
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Figure 37: Predicted patient profiles by first 24 hour parasite reduction ratios
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Figure 38: Observed Gametocyte mean profiles (black circles) for selected pa-
tients superimposed with predicted mean profiles using the ZAG model (red
line) and the ZAGJWC model (blue line). The first row consists of patients
who were observed at all observations days. The remaining rows are examples
of incomplete gametocyte profiles with the second row consists of patients who
experienced treatment failure with the third row consisting of patients lost-to-
follow-up
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4.11 Estimation of the duration of gametocytemia using
imputed gametocyte profiles
In Chapter 3 an analysis into the time to gametocyte clearance was conducted.
In that analysis it was assumed that gametocyte clearance occurred in the mid-
dle of adjacent observation days. This was a simplistic assumption used to ac-
count for interval censoring. In this Chapter a ZAGJWC (zero-adjusted gamma
nonlinear joint model with a Weibull cause-specific survival component) model
was developed. This model can be used to impute incomplete gametocyte pro-
files whilst accounting for informative censoring. These imputed profiles would
provide estimates for all missing observations, including observations that would
lie in-between patient follow up days. These complete gametocyte profiles can
thus be used to investigate the risk factors that influence a more precisely de-
fined time to gametocyte clearance and subsequently be used to estimate the
duration of gametocytemia. The use of these imputed profiles, in an investi-
gation to estimate the duration of gametocytemia, would mitigate the effect of
interval censoring on the model estimation procedure.
The procedure outlined in Chapter 4.9 was used to derive estimates for a
Weibull AFT model, applied to imputed profiles within the iterative imputation
algorithm, designed to estimate the duration of gametocytemia in patients. The
survival model results are presented in Table 30. This table also provides a
comparison with the fitted Weibull AFT model from Chapter 3, which is referred
to as the “Original” model.
Table 30: Comparison of Weibull AFT models (95% CI).
Definition Parameter Original Imputed
intercept α0 1.281 (0.661 ; 1.902) 1.817 (0.959 ; 2.370)
trt α1 -1.022 (-1.401 ; -0.643) -0.778 (-1.710 ; -0.286)
ratio α2 -0.224 (-0.484 ; 0.037) -0.183 (-0.471 ; 0.131)
anaemia α3 0.005 (-0.214 ; 0.223) -0.109 (-0.477 ; 0.096)
mut5 α4 0.041 (-0.229 ; 0.311) -0.151 (-0.756 ; 0.139)
lage α5 0.046 (-0.034 ; 0.125) 0.065 (-0.009 ; 0.151)
pzero α6 0.096 (0.058 ; 0.134) 0.092 (0.053 ; 0.141)
gender α7 0.120 (-0.091 ; 0.330) 0.022 (-0.237 ; 0.314)
scale σ 0.711 (0.631 ; 0.790) 0.804 (0.632 ; 1.130)
Table 30 reveals that, under the imputed model, patient age has a marginal
association with the time to gametocyte clearance (as shown by the predomi-
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nately positive 95% CI for this parameter). The implication is that doubling
patient age leads to a 6.8% increase in the time to gametocyte clearance, un-
der the imputed model. The magnitude of the treatment effect was found to
have changed considerably between the two models. Receiving a combination
treatment of artesunate and sulfadoxine-pyrimethamine was found to reduce
the time to gametocyte clearance by 54.1%, under the imputed model, whilst it
reduced the time to gametocyte clearance by 64% under the “original” model.
The magnitude of the effect associated with the first 24 hour parasite reduc-
tion ratio and the baseline asexual parasite density, did not change considerably
between the two models. Under the imputed model, clearing all baseline asex-
ual parasites in the first 24 hours reduces the time to gametocyte clearance by
16.7% as compared to the “original” model, where clearing all baseline asex-
ual parasites in the first 24 hours reduces the time to gametocyte clearance
by 20%. Every ten fold increase in the baseline asexual parasite density leads
to a 9.6% increase in the time to gametocyte clearance, when considering the
imputed model, as compared to a 10.1% increase under the “original” model.
It is also evident from Table 30 that the effects of the prevalence of moderate
anaemia, prevalence of quintuple mutations and patient gender, do not have an
association with the time to gametocyte clearance.
The approach taken to derive the time to gametocyte clearance parameter
estimates, from the ZAGJWC model, was also applied to derive parameter
estimates for the prevalence of gametocytemia model. The results are shown in
Table 31. It can be seen that there is a marginal difference, in the parameter
estimates, between the model fit in Chapter 3 and the model resulting from
the imputed gametocyte profiles. It can also be seen that the strength of the
association between treatment and the prevalence of gametocytemia is reduced,
when comparing the treatment effect in the imputed model to the original model.
An additional finding is that the prevalence of mutation can be seen to have a
strong association with the prevalence of gametocytemia in the imputed model
(the presence of quintuple mutations increases the relative risk of gametocytemia
by 18.3%), whilst it previously had no association under the original model.
As previously discussed, estimates for the duration of gametocytemia that
were derived from the Weibull AFT model would only be valid for the cohort
of patients who experienced gametocytemia. An adjustment would be required
to derive population level duration estimates for generic patients with specific
covariate patterns. This adjustment would require that the estimated prevalence
of gametocytemia be combined with the estimated duration of gametocytemia,
for a generic patient with a specific covariate pattern. Given that the duration of
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Table 31: Comparison of gametocyte prevalence models (95% CI).
Definition Parameter Original Imputed
intercept βB0 -1.597 (-2.159 ; -1.034) -1.500 (-1.893 ; -0.821)
trt βB1 -0.766 (-1.134 ; -0.397) -0.644 (-1.024 ; 0.040)
ratio βB2 -0.461 (-0.723 ; -0.199) -0.416 (-0.585 ; -0.204)
anaemia βB3 0.171 (-0.015 ; 0.357) 0.181 (0.062 ; 0.346)
mut5 βB4 0.128 (-0.070 ; 0.326) 0.168 (0.045 ; 0.397)
lage βB5 0.012 (-0.053 ; 0.077) 0.017 (-0.025 ; 0.054)
pzero βB6 0.053 (0.020 ; 0.087) 0.049 (0.003 ; 0.073)
gender βB7 0.208 (0.030 ; 0.387) 0.181 (0.033 ; 0.302)
gametocytemia for a generic patient with a specific covariate pattern is defined
as si with the prevalence of gametocytemia for the same patient given πi, the
resulting adjusted duration (di) would be given as
di = si × πi.
A dataset of generic patients was created to illustrate the impact of specific
covariate patterns on the estimated duration and adjusted duration of gameto-
cytemia. The dataset that was created was similar to the one used to derive
Table 17 in Chapter 3. The dataset applied in this section allows for compar-
isons to be made on the covariates that were found to have a strong association
with the time to gametocyte clearance, under the imputed survival model. The
following characteristics were compared in this table
• Sulfadoxine-pyrimethamine treatment only (SP) and a combination treat-
ment of artesunate and sulfadoxine-pyrimethamine (ACT)
• “High” log10 baseline parasite density of 17.754 relative to a “Low” base-
line parasite density of 5
• “High” first 24 hour parasite reduction ratio of 100% relative to a “Low”
first 24 hour parasite reduction ratio of -31.4%
• “Old” patient with an age of 55.0 (lage = 5.781) relative to “Young”
patient with age of 2 (lage = 1)
These results are presented, in Table 32, for a female with a haemoglobin density
greater than 11g/dL and less than 5 mutations present. It can be seen that
patients who would have the longest duration have the following characteristics
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• Receive sulfadoxine-pyrimethamine (SP) treatment only
• Have a high baseline asexual parasite density
• Have a low first 24 hour parasite reduction ratio











































































































































































































































































































































































































































































































































































































































It has been shown in this thesis, when considering the results of the ZAGJWC
(zero-adjusted gamma nonlinear joint model with a Weibull cause-specific sur-
vival component) model, that treatment has a strong association with the haz-
ard of treatment failure and the hazard of loss-to-follow-up (Table 27). It was
found that receiving a combination treatment of artesunate and sulfadoxine-
pyrimethamine (ACT) decreased the hazard of treatment failure by 94%, whilst
increasing the hazard of loss-to-follow-up by 289 fold. The implication of these
findings is that the treatment administered to a patient is strongly associated
with treatment outcome. Patients who experienced treatment failure are thus
closely associated with patients who received SP treatment whilst patients who
were lost-to-follow-up are associated with patients who received a combination
treatment of artesunate and sulfadoxine-pyrimethamine (ACT). Based on these
findings it can be concluded that patients who experience treatment failure are
expected to have longer durations of gametocytemia as compared to patients
who are lost-to-follow-up.
Baseline asexual parasite density was found to have strong association with
the hazard of treatment failure with a ten-fold increase in the baseline asexual
parasite density resulting in a 21.7% increase in the hazard of treatment failure
(Table 27). Baseline asexual parasite density was also found to have a strong
association with the prevalence of and duration of gametocytemia analyses con-
ducted using the imputed gametocyte profiles from the ZAGJWC model. It was
found that a ten fold increase in the baseline asexual parasite density resulted
in a 5.0% increase in the relative risk of gametocytemia and a 9.6% increase in
the time to gametocyte clearance.
The prevalence of quintuple mutations was used as a measure of resistance to
treatment in this thesis. It was found that the prevalence of quintuple mutations
had a strong association with the hazard of treatment failure, with the presence
of quintuple mutations leading to a 21.7% increase in the hazard of treatment
failure. There was no association between the prevalence of quintuple mutations
and the hazard of loss-to-follow-up. It was found that the prevalence of quintuple
mutations had a strong association with the prevalence of gametocytemia (the
presence of quintuple mutations leads to a 18.3% increase in the relative risk
of gametocytemia), when considering the analysis conducted using the imputed
gametocyte profiles from the ZAGJWC model. The impact of the prevalence
of quintuple mutations is as expected in literature and this result signifies an
improvement from the prevalence of gametocytemia model derived in Chapter
3. It was also highlighted that the prevalence of quintuple mutations did not
have an association with the duration of gametocytemia, in either the original
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model or the imputed model.
The first 24 hour parasite reduction ratio was also found to have a strong
association with the hazard of treatment failure, whilst not having an association
with the hazard of loss-to-follow-up. Clearing all baseline asexual parasites
in the first 24 hours was found to lead to a 94.6% reduction in the hazard
of treatment failure, under the ZAGJWC model. The first 24 hour parasite
reduction ratio was found to have a strong association with the prevalence of
gametocytemia (clearing all baseline asexual parasites in the first 24 hours leads
to a 34.0% reduction in the relative risk of gametocytemia), when considering
the imputed model. The first 24 hour parasite reduction ratio was found to
have no association with the duration of gametocytemia.
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5 Discussion
Gametocytes are the sexual form of the Plasmodium falciparum parasite and
they have been found to have a significant influence on the infectivity of a
host patient. Most malaria intervention trials focus on the clearance of asexual
parasites, which are responsible for the signs and symptoms associated with
malaria infection. An effective treatment is one that can quickly and efficiently
clear both forms of the Plasmodium falciparum parasite.
The main aim of this thesis was the imputation of the incomplete game-
tocyte profile in the presence of censoring. The clinical motivation for this
analysis was that research into the risk factors that influence the emergence of
gametocytes, duration of gametocytemia and density of gametocytes is of vital
public health importance as the findings from such work can be used to reduce
the transmission of malaria and subsequently the spread of antimalarial drug
resistance.
There is also a methodological motivation for this analysis. Gametocyte
data is characterized by being zero inflated, skew with a long-tail to the right
and nonlinear with regards to the relationship between the gametocyte density
profile and time. There is also a competing risk nature associated with the
different reasons for early exit from the study. These features of gametocyte
data make it a statistically appealing dataset to analyze. In order to answer
the clinical questions raised above, joint modeling techniques based on cause-
specific Weibull models for the times to early exit and zero-adjusted gamma
models for the longitudinal profiles had to be developed.
This chapter will be split into methodological and clinical discussion sections.
5.1 Methodological discussion
The gametocyte data used in this investigation was found to be zero-inflated
with a long-tail to the right. The observed longitudinal gametocyte profiles, of
patients included in this analysis, were found to have a nonlinear relationship
with time. Another feature of this data was the presence of censoring. Some
patients exited the study before its completion either due to treatment failure
or loss-to-follow-up. It was found that the experience of patients who exited the
study early was different to that of patients who remained, thus implying that
this exit was a form of informative censoring. Additionally it was found that
there was a competing risks nature to the forms of early exit from the study.
Patients who withdrew from the study either due to treatment failure or loss-
to-follow-up had incomplete gametocyte profiles. It can reasonably be assumed
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that the gametocyte profiles of patients who were rescued from the study or
who were lost-to-follow-up (assuming informative censoring) would differ from
the observed profiles of patients who were successfully treated and observed to
the end of the gametocyte cycle.
Longitudinal nonlinear profiles are typically modeled using nonlinear mixed
effect models. These models typically assume an underlying normal distribu-
tion for the response. Since gametocyte data are zero-inflated with a long-tail
to the right, the assumption of normality is not be valid. This distributional as-
sumption can be changed, with the response assumed to follow a zero-adjusted
gamma distribution. Making this change would allow for a standard nonlinear
mixed effect model to be fit. However, standard nonlinear mixed effect models
rely on model based imputation due to maximum likelihood estimation in the
presence of missing data. Hence these models do not account for informative
censoring, which can lead to biased parameter estimates.
These aforementioned problems were overcome by using joint modeling tech-
niques based on cause-specific Weibull models for the times to early exit and
zero-adjusted gamma models for the longitudinal profiles. The resulting joint
model used shared random effects to combine a Weibull survival model, describ-
ing the cause-specific hazards of patient exit from the study, with a nonlinear
zero-adjusted gamma mixed effect model for the longitudinal gametocyte profile
(ZAGJWC model). Table 29 compared the longitudinal parameter estimates of
the zero-adjusted gamma mixed effect (ZAG) and the ZAGJWC models. It was
shown that there were noticeable differences in the magnitude of the fixed ef-
fects across the ZAG and ZAGJWC models. In some cases parameters that were
found to have no association with the longitudinal gametocyte profile, under the
ZAG model, were found to have a strong association with the gametocyte profile
once a ZAGJWC model was applied. A comparison of the observed gametocyte
profiles for select patients from the study, along with the fitted values from both
the ZAG and ZAGJWC models, was illustrated graphically in Figure 38. This
graphic revealed that the ZAGJWC predicted profiles outperformed the ZAG
across the group of patients who were observed at all timepoints. However, it
was observed that there was a small difference between the models when predic-
tions were made on incomplete profiles. The development of additional model
comparison techniques is thus an area of further research that would enrich this
analysis and provide further backing to the assertion that the ZAGJWC model
is a better model as compared to the ZAG model.
It was shown in Table 26 and Table 27 that several precision parameters
could arguably be omitted from the fitted joint models. However, these random
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effects were retained in the models as they captured the within subject correlated
structure. These random effects were also retained as they allowed for an easy
comparison of the different model structures fit to the data.
Complex likelihood functions were developed in order to fit the joint models
described above. These functions were estimated under the Bayesian framework.
The resulting joint posterior distributions for the parameters were analytically
intractable thus Markov Chain Monte Carlo (MCMC) methods were used to ob-
tain the point and interval estimates of parameters. The imputed gametocyte
profiles were derived from posterior samples generated as part of the Bayesian
MCMC procedure used in the development of the applicable joint model. These
completed profiles would provide estimates for all missing data, including miss-
ing data arising in-between the predefined study observation days.
The complete gametocyte profiles were subsequently used in an analysis to
investigate the risk factors that affect the prevalence of gametocytemia and the
time to gametocyte clearance. The advantages of using imputed gametocyte
profiles are that they account for informative censoring and they mitigate the
effect of interval censoring as predicted responses can be generated for the time-
points that lie in-between the study’s predefined observation dates. It was found
that the use of the imputed data improved the results of the analysis. This was
highlighted by the prevalence of quintuple mutations (used as a measure of re-
sistance to treatment in this thesis) which was found to have no association
with the prevalence of gametocytemia, when considering the observed data.
However, when the imputed data was analyzed a strong association was found
between the prevalence of quintuple mutations and the prevalence of gameto-
cytemia. This association is as expected in literature and this result highlights
the improvement in analysis arising from the use of imputed data derived from
the ZAGJWC model.
An unfortunate drawback of the methodology developed above is that it is
computationally intensive due to the complexity of the fitted models. It took
2 days to fit the ZAGJWC model using a laptop with an i7 processor, 64-bit
operating system and 8GB RAM. It is hoped that with future advancements in
computational power, the running time for these models would decrease.
The treatment administered to a patient was found to have a strong associa-
tion with the patient’s treatment outcome. Treatment outcome provided infor-
mation used in the imputation of the longitudinal gametocyte profile through
the cause-specific survival component of the ZAGJWC model. Generally a pa-
tient’s response to treatment depends on the immunity level of the host, the
level of Plasmodium falciparum parasite resistance to treatment and the phar-
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macokinetic properties of the antimalarial treatment. The models considered
in this thesis did not account for the pharmacokinetic properties of the anti-
malarial treatment. The work conducted in this thesis can thus be extended
to include the evolution of patient drug concentrations in the longitudinal ga-
metocyte model. The expectation is that adding the pharmacokinetics of the
drugs administered to the patient would improve the performance of the fitted
models.
An additional methodological innovation that was discussed in this thesis
was the development of a framework for the estimation of population level ga-
metocyte duration estimates, for patients with specific covariate patterns. This
methodology combined estimates for the prevalence of gametocytemia with es-
timates for the duration of gametocytemia to give an expected population level
estimate for the duration of gametocytemia, with an associated confidence inter-
val derived using the delta method. A simplifying assumption of independence
between the duration of gametocytemia and the prevalence of gametocytemia
was applied in the derivation of the variance structure for the estimated pop-
ulation level duration estimates. It is acknowledged that there could possibly
be a correlation between the duration of gametocytemia and the prevalence of
gametocytemia. An investigation into the appropriateness of the independence
assumption and the resulting change in the variance structure of the popula-
tion level duration estimates, assuming that the independence assumption is not
appropriate, is an area of further work.
An additional area of further work, is the design of an optimal cost effective
study that is able to capture data at key points of the gametocyte life cycle.
Currently the majority of malaria intervention studies are designed to capture
the evolution of the asexual parasites, resulting in sparse observations in the
periods when gametocyte are expected to be prevalent. The methodology used
to impute incomplete gametocyte profiles, which was outlined in this study, can
be used to estimate time periods of high gametocyte prevalence. Subsequently
studies can be designed that capture gametocyte data at these key points.
5.2 Clinical discussion
Since 2000 there has been a considerable reduction in the global malaria bur-
den. This has been associated with the wide-scale deployment of artemisinin
based combination therapies in malaria endemic countries. Artemisinin based
treatments work quickly and efficiently against asexual parasites (White, 1997)
and immature gametocytes (Adjalley et al., 2011, Price et al., 1996). As a re-
sult these treatments are associated with high patient cure rates and low post-
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treatment malaria transmission (Group et al., 2016). Unfortunately over the
last few years artemisinin resistance has been confirmed in the Greater Mekong
Subregion, in countries like Cambodia, the Lao Peoples Democratic Republic,
Myanmar, Thailand and Vietnam. In most cases, patients with artemisinin-
resistant parasites are still able to achieve an adequate clinical and parasito-
logical response if the longer-acting partner drug used in conjunction with the
artemisinin derivate is still effective in that geographical area. However, it has
been found that Plasmodium falciparum has become resistant to almost all
available antimalarial treatments in areas along the Cambodia-Thailand bor-
der (WHO, 2013). It is thus imperative that this treatment resistant strain is
stopped from spreading. Currently a single dose of primaquine is recommended,
by the WHO (WHO, 2017b), to be used in conjunction with artemisinin in or-
der to prevent transmission of Plasmodium falciparum to mosquitoes in areas
threatened by artemisinin resistance. Research into the risk factors that affect
the prevalence gametocytemia, duration of gametocytemia and the density of
gametocytes is of vital importance to public health. This is because a decrease
gametocyte carriage does not just reduce ongoing malaria transmission, but it
can also slow down the spread of antimalarial drug resistance that is threatening
current malaria control and elimination efforts.
The modeling of the key features of gametocytemia, was an area of focus in
this thesis. Particular emphasis was placed on the modeling of the time to ga-
metocyte emergence, prevalence of gametocytemia, duration of gametocytemia
and the density of gametocytes. It was also of interest to investigate the impact
of current and novel antimalarials under development on the aforementioned
features.
The data used in this analysis was from a series of clinical trials conducted
between 2002 and 2004 in southern Mozambique and the Mpumulanga province
of South Africa. The aim of these studies was primarily to measure the effi-
cacy of two treatments, in eliminating asexual parasites in patients. The two
treatment procedures used were sulfadoxine-pyrimethamine (SP) only and a
combination of artesunate and sulfadoxine-pyrimethamine (ACT). The patients
enrolled in the trials had moderate uncomplicated malaria, in a period of in-
creasing resistance to sulfadoxine-pyrimethamine (SP) treatment.
The gametocyte data collected in this study was initially analyzed using
standard survival modeling techniques. Non-parametric Cox regression models
and parametric survival models were applied to the data as part of this initial
investigation. These models were used to investigate the factors that affected
the time to gametocyte emergence. Subsequently, using the subset of the pop-
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ulation that experienced gametocytemia, accelerated failure time models were
applied to investigate the factors that affected the duration of gametocytemia.
It is evident that the findings from the aforementioned duration investigation
would only be able to provide valid duration estimates for patients who expe-
rienced gametocytemia. This work was extended to allow for population level
duration estimates by incorporating the prevalence of gametocytemia into the
estimation of duration. The prevalence of gametocytemia was modeled using
an underlying binomial distribution. The delta method was subsequently used
to derive confidence intervals for the population level duration estimates that
were associated with specific covariate patterns.
The gametocyte data used in this analysis was collected over a 42 day follow
up period with observations occurring on days 0, 3, 7, 14, 21, 28 and 42. Due to
the design of the study, it is evident that in addition to informative censoring,
interval censoring would also be expected to arise. The previously discussed
accelerated failure time models, which were used to investigate the factors that
affected the duration of gametocytemia, applied a simplistic approach to the
analysis of the gametocyte clearance data. It was assumed that gametocyte
clearance occurred in the middle of adjacent observation days, with this mid-
point used as a point estimate for the gametocyte clearance time. The findings
from the investigation into the duration of gametocytemia were updated by tak-
ing the imputed profiles, derived as part of the fitting process for the ZAGJWC
model and then subsequently using them to estimate the duration of gameto-
cytemia. The use of these imputed profiles mitigated the effect of informative
censoring and interval censoring on the resulting analysis.
The results of the updated time to gametocyte clearance analysis (results
shown in Table 30) highlighted that a patient’s treatment had a strong associ-
ation with the duration of gametocytemia. It was found that receiving a com-
bination of artesunate and sulfadoxine-pyrimethamine treatment as compared
to sulfadoxine-pyrimethamine treatment only, decreases the time to gametocyte
clearance by 54.1%. The density of baseline asexual parasites was also found to
have a strong effect on the duration of gametocytemia, with a ten-fold increase
in the baseline asexual parasite density leading to a 9.6% increase in the time
to gametocyte clearance. It was also found that patient age has a marginally
strong association with the time to gametocyte clearance, as doubling patient
age leads to a 6.8% increase in the time to gametocyte clearance. In literature,
increased age is usually associated with lower gametocyte carriage (in areas of
moderate to intense malaria transmission such as Mozambique where partial
immunity is acquired with age), or has no effect on gametocyte carriage (in
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non-immune patients such as those living in areas of low intensity transmission,
e.g. Mpumalanga). It is thus unusual that the results of this analysis imply
that increasing age leads to an increase in the duration of gametocytemia. A
possible reason for this result is that patients from different study sites were
combined for the purposes of this investigation. As previously discussed the
impact of age is dependent on the malaria transmission rates associated with
the site of the study, as a result an improvement in the interpretation of the
results might occur if study site is incorporated into the model.
The imputed gametocyte profiles from the ZAGJWC model were used to
derive a prevalence of gametocytemia model (results shown in Table 31). It was
found that treatment had a marginal association with the prevalence of gameto-
cytemia, as the 95% CI for the parameter estimate was predominately negative.
The first 24 hour parasite reduction ratio, the prevalence of anaemia, the preva-
lence of quintuple mutations, baseline asexual parasite density and gender were
all found to have strong associations with the relative risk of gametocytemia.
It is interesting to note that the prevalence of gametocytemia model derived in
Chapter 3 found that the prevalence of quintuple mutations had no association
with the prevalence of gametocytemia. The use of imputed gametocyte profiles
increases the strength of the association between the prevalence of quintuple
mutations and the prevalence of gametocytemia. The association between the
prevalence of quintuple mutations and the prevalence of gametocytemia makes
clinical sense and it is as expected from literature. The same applies for the
prevalence of moderate anaemia, as this covariate was found to have no asso-
ciation with the prevalence of gametocytemia in the model fit in Chapter 3.
However, the use of imputed gametocyte profiles increased the strength of the
association between the prevalence of moderate anemia and the prevalence of
gametocytemia. The model derived from the imputed gametocyte profiles can
be intercepted as
• Receiving a combination of artesunate and sulfadoxine-pyrimethamine
(ACT) reduces the relative risk of gametocytemia by 47.4% as compared
to receiving sulfadoxine-pyrimethamine treatment only
• Clearing all baseline asexual parasites in the first 24 hours reduces the
relative hazard of gametocytemia by 34.0%
• The presence of moderate anaemia increases in the relative risk of game-
tocytemia by 19.8%
• The presence of quintuple mutations increases the relative risk of game-
tocytemia by 18.3%
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• A ten-fold increase in the baseline asexual parasite density increases the
relative risk of gametocytemia by 5.0%
• Being a male patient increases the relative risk of gametocytemia by 19.8%
The prevalence of quintuple mutations and the first 24 hour parasite reduction
ratios did not have an association with the duration of gametocytemia, in either
of the original model (derived from Chapter 3) or the imputed (derived using
imputed gametocyte profiles from the ZAGJWC model) models. These results
are unexpected as the initial assumption around the impact of resistance to
treatment and the first 24 hour parasite reduction ratio was that these covariates
would affect both the prevalence and duration of gametocytemia. Further work
is required in order to understand the aforementioned findings.
In summary, the key findings from this investigation were that treatment
had a highly significant effect on the time to gametocyte emergence, extent
of gametocytemia and the duration of gametocytemia. Patients who received a
combination of artesunate and sulfadoxine-pyrimethamine treatment were found
to have significantly lower hazards of gametocyte emergence, lower predicted
durations of gametocytemia and lower predicted longitudinal gametocyte den-
sities, as compared to patients who received sulfadoxine-pyrimethamine treat-
ment only. It was also shown that the impact of a combination of artesunate and
sulfadoxine-pyrimethamine treatment on the gametocyte density was stronger
than the impact of all the other covariates considered in this study. This result
implies that regardless of a patient’s covariate pattern, the application of a com-
bination artesunate and sulfadoxine-pyrimethamine treatment will suppress the
gametocyte density. This is a powerful result that highlights the importance of
artemisinin based treatment to the fight against malaria, as this treatment can
be seen to have a significant effect on the key driver of malaria transmission.
A reduction in the transmission rate of malaria in a community can also lead
to a reduction in the spread of antimalarial drug resistance, that is threatening
current malaria control and elimination efforts.
5.3 Concluding remarks
The overall contribution of this piece of work was that a methodology was devel-
oped that allowed for the imputation of incomplete gametocyte profiles, whilst
taking into account informative censoring and the underlying structure of the
longitudinal gametocyte patient profile, through the use joint modeling tech-
niques. The imputed gametocyte profiles were derived from posterior samples
generated as part of the Bayesian MCMC procedure used in the development
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of the applicable joint model. The resulting joint model used shared random ef-
fects to combine a Weibull survival model, describing the cause-specific hazards
of patient exit from the study, with a nonlinear zero-adjusted gamma mixed
effect model for the longitudinal gametocyte profile. This model was used to
impute the incomplete gametocyte profiles, after adjusting for informative cen-
soring. These imputed profiles were then used to identify the risk factors that
influence the duration and prevalence of gametocytemia. An additional contri-
bution of this work was the development of a methodology for the estimation of
population level gametocyte duration estimates. This methodology combined
estimates for the prevalence of gametocytemia with estimates for the duration
of gametocytemia to give an expected population level estimate for the duration
of gametocytemia with an associated confidence interval, derived using the delta
method.
It is hoped that the findings from this research will be incorporated into the
continuous fight against malaria infection and transmission.
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6 Appendix
6.1 Modified critical exponential nonlinear mixed effects







C[i]<- betaC0+ (betaC1 * trt[i]) + (betaC2 * ratio[i]) + (betaC3 * anaemia[i])
+(betaC4 * mut5[i]) + (betaC5 * lage[i]) +(pzero[i]*betaC6)+ (sex[i]*betaC7) + c[i]
R[i]<- betaR0+ (betaR1 * trt[i]) + (betaR2 * ratio[i]) + (betaR3 * anaemia[i])



































































6.3 Normally distributed Joint model, with Weibull cause-
specific hazard survival component model, used for










censoredF[i] ~ dinterval(tF[i], cenF[i])
log(muF[i])<-betaF0+(trt[i]*betaF1)+(ratio[i]*betaF2)+(anaemia[i]*betaF3)+(mut5[i]*betaF4)




censoredL[i] ~ dinterval(tL[i], cenL[i])
log(muL[i])<-betaL0+(trt[i]*betaL1)+(ratio[i]*betaL2)+(anaemia[i]*betaL3)+(mut5[i]*betaL4)






C[i]<- betaC0+ (betaC1 * trt[i]) + (betaC2 * ratio[i]) + (betaC3 * anaemia[i]) +
(betaC4 * mut5[i]) + (betaC5 * lage[i]) +(pzero[i]*betaC6)+ (sex[i]*betaC7) + c[i]
R[i]<- betaR0+ (betaR1 * trt[i]) + (betaR2 * ratio[i]) + (betaR3 * anaemia[i]) +



















































6.4 Zero-adjusted gamma Joint model, with Weibull cause-
specific hazard survival component model, used for








#Treatment Failure cause of exit
tF[i]~dweib(wF,muF[i])
censoredF[i] ~ dinterval(tF[i], cenF[i])
log(muF[i])<-betaF0+(trt[i]*betaF1)+(ratio[i]*betaF2)+(anaemia[i]*betaF3)
+(mut5[i]*betaF4)+(lage[i]*betaF5)+ (pzero[i]*betaF6)+ (sex[i]*betaF7)
+ (cf*c[i])+ (rf*r[i]) + (brf* br[i]) + (bcf* bc[i])
#LTFU cause of exit
tL[i]~dweib(wL,muL[i])
censoredL[i] ~ dinterval(tL[i], cenL[i])
log(muL[i])<-betaL0+(trt[i]*betaL1)+(ratio[i]*betaL2)+(anaemia[i]*betaL3)
+(mut5[i]*betaL4)+(lage[i]*betaL5) + (pzero[i]*betaL6)







A[i]<- betaA0 + (betaA1 * trt[i]) + (betaA2 * ratio[i]) + (betaA3 * anaemia[i])
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+ (betaA4 * mut5[i]) + (betaA5 * lage[i])+ (betaA6 * pzero[i])+ (sex[i]*betaA7)
C[i]<- betaC0 + (betaC1 * trt[i]) + (betaC2 * ratio[i]) + (betaC3 * anaemia[i])
+ (betaC4 * mut5[i]) + (betaC5 * lage[i])+ (betaC6 * pzero[i])+ (sex[i]*betaC7) + c[i]
R[i]<- betaR0 + (betaR1 * trt[i]) + (betaR2 * ratio[i]) + (betaR3 * anaemia[i])




bA[i]<- betaBA0 + (betaBA1 * trt[i]) + (betaBA2 * ratio[i]) + (betaBA3 * anaemia[i])
+ (betaBA4 * mut5[i]) + (betaBA5 * lage[i])+ (betaBA6 * pzero[i])+ (sex[i]*betaBA7)
bC[i]<- betaBC0 + (betaBC1 * trt[i]) + (betaBC2 * ratio[i]) + (betaBC3 * anaemia[i])
+ (betaBC4 * mut5[i]) + (betaBC5 * lage[i])+ (betaBC6 * pzero[i])+(sex[i]*betaBC7)+ bc[i]
bR[i]<- betaBR0 + (betaBR1 * trt[i]) + (betaBR2 * ratio[i]) + (betaBR3 * anaemia[i])








logit(PI[i,j]) <- bA[i] + ((bC[i]* pday[i,j] ) * pow(bR[i],pday[i,j]) )
#gamma





l[i,j] <- ((1-d[i,j])* log(1-PI[i,j])) + (d[i,j] * (log(PI[i,j]) + logGamma[i,j]))





















































































#prior distributions for the missing response values excluded in the above extract
}
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